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CHAPTER 1 
INTRODUCTION 
Part of this chapter was previously published: 
PAJ Speth, H Minderman, С Haanen. Idarubicin ν Daunorubicin: Preclinical 
and clinical pharmacokinetic studies. Seminars in Oncology vol 16 (1), 
suppl2:2-9, 1989. 

Chapter 1: Introduction 
A commonly used treatment modality against cancer is chemotherapy. 
The first documented clinical use of chemotherapy was in 1942 when 
nitrogen mustard was used to obtain a brief clinical remission in a patient 
with lymphoma [1]. Since then, many drugs have been developed and tested 
for potential clinical activity. 
1. THE ANTHRACYCLINES. 
The anthracyclines form a large family of drugs with a wide spectrum 
of antitumor activity, they are among the most widely applied in cancer 
chemotherapy. Although many anthracycline derivatives have been 
synthesized over the years, doxorubicin and daunorubicin still remain to be 
the most prominent representatives with clinical application in the treatment 
of solid tumors as well as hematological cancers. However, the need for new 
drugs in oncology is still actual, because for most patients with acute 
nonlymphocytic leukemia or solid tumors who attain a clinically complete 
remission, a relapse occurs within months to years. Apparently, current 
anticancer treatment produces only a reduction of a limited number of 
clonogenic (tumor) cells, thus leaving a minimal, but ultimately fatal, 
number of residual tumor cells alive. Present anthracycline therapy of acute 
leukemias and solid tumors has been limited by a lack of differential kill 
between tumor cells and normal (hematopoietic) cells [13,14], and the 
occurence of systemic toxicity (heart, mucosa, normal hematopoiesis) [15-
17], limiting the amount of drug to be given. In search for new 
anthracyclines with a higher therapeutic index, idarubicin; (4-
demethoxydaunomycin), Ida) has emerged. Ida has been under experimental 
and clinical investigation for over a decade. On a chemical basis, the 
differences between Doxorubicin (Dox), Daunorubicin (Dnr), and Idarubicin 
(Ida) are relatively small. Dox differs from Dnr by one hydroxylgroup while 
Ida only differs from Dnr by the lack of one methoxyl group. 
2. IDARUBICIN V DAUNORUBICIN; PRECLINICAL AND 
CLINICAL PHARMACOKINETIC STUDIES 
The small difference in the molecular structure between Dnr and Ida 
produced an enormous shift in the lipophilicity, expressed in partition 
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coefficients of 27.7 (Ida) and 15.3 (Dnr), respectively [18]. The greater 
lipophilicity of Ida explains at least part of the higher Ida uptake in tissue 
compared with the uptake of Dnr. Although, compared to Dnr, Ida is 
cytotoxic at relatively low dosages, the binding of Ida to DNA or inhibition 
of DNA and RNA polymerases was equal for both drugs [18], insofar as 
considerable interindividual differences in DNA damage have been noted 
[19]. Ida has been reported to have higher antitumor [20] and antileukemic 
activity [21] than Dnr with reduced cardiotoxicity [15]. Below, the 
pharmacokinetic data of Ida and Dnr obtained from in vitro studies, animal 
studies, and clinical studies, will be discussed with special emphasis on 
leukemia. 
2.1 IN VITRO PHARMACOKINETIC STUDIES 
Human bone marrow cells were prepared for in vitro studies [22]. 
Nucleated cells were exposed to Ida and Dnr (Specia, Paris) at 25 and 100 
ng/ml, respectively, for 360 minutes.Medium concentrations and mean 
cellular drug concentrations were determined with high-pressure liquid 
chromatography (HPLC) [22]. Cellular drug concentrations in 
subpopulations of hematopoietic cells were measured with flow cytometry 
[23]. In vitro drug uptake was linear up to medium concentrations of over 
5,000 ng/ml. This points to a large quantity of binding sites which had not 
been occupied even at these high supraphysiologic dosages. 
After 360 minutes of incubation, cellular accumulation of Ida was 
twice that of idarubicinol (Idaol) or Dnr; cellular drug concentrations (ng/10* 
cells) were 480 (Ida), 280 (Idaol), 260 (Dnr), and 85 (daunorubicinol, Dnrol) 
times the medium drug concentration (unpublished data). Due to this high 
cellular uptake, a considerable decrease in drug per cell occured at 
increasing cell densities (data not shown). The extent and the rate of cellular 
drug uptake have been related to the partition coefficient [15,24,25]. The 
uptake of Ida into human hematopoietic cells is almost twice as fast as that 
of Idaol or Dnr. Similar results have been reported for fibroblasts [26]. 
Cellular Ida concentrations in human bone marrow cells reached a plateau at 
30 to 60 minutes for lymphocytes and monocytes/blast cells, whereas for 
myeloid cells it took approximately two to three hours to reach steady state 
levels [fig 1.1]. The total cellular drug concentration in lymphocytes is 
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approximately 50% lower than the levels reached in monocytes/blasts cells 
and myeloid cells [24]. In case of exposure to Dnr, steady state levels were 
not reached during 360 minutes of incubation. Also, efflux from the cells at 
reincubation in drug-free medium showed characteristic differences [figure 
1.1], Ida efflux being more extensive and at a higher rate [24]. In the 
absence of erythrocytes, metabolism to the 13-OH-metabolite was minimal; 
addition of red cells produced the formation of some Idaol in vitro 
(unpublished data). 
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FIGURE 1.1 
In vitro cellular anthra-
cycline uptake and efflux in 
human hematopoietic cells. 
10^ cells/ml were incubated 
for 360 minutes with 100 
ng/ml Dnr ( cross ) , and 25 
ng/ml Ida ( open squares ) , 
and reincubated in drug-free 
medium for 180 minutes, (a) 
lymphocytes, (b) monocytes / 
blasts, (c) myeloid cells. 
Adapted with permission 
/24]. 
2.2. IN VITRO CYTOTOXICITY 
Ida inhibited the clonogenicity of cell lines from several origins -
amongst others leukemia, sarcoma, and breast carcinoma- to a higher degree 
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than Dnr [27,28]. Activity of Idaol in vitro was close to the activity of Ida 
[29]. Dnrol appeared to have lower cytotoxic activity in vitro and in vivo, 
compared with the parent drug. Cellular Dnrol uptake is lower, related to the 
lower partition coefficient of Dnrol [15,23]. Cells from bone marrow of 
normal donors or AML patients were incubated with Ida (0.003 to 1 ng/ml) 
or Dnr (0.03 to 5 ng/rnl) for one hour at 37°C [13]. Cells were seeded and 
surviving colony-forming cells were estimated [figure 1.2] in CFU-GM 
(normal myeloid colony forming cells), BFU-E (erythroid colony forming 
cells), and AML-CFU (AML colony forming cells) [13]. Ida was equally, or 
even more toxic to normal human bone marrow precursors (inhibitory dose, 
ID50, was approximately 0.007 μg/ml for Ida and 0.1 μg/ml for Dnr), with a 
rather narrow range [13]. A comparable pattern of cytotoxicity was observed 
toward AML clonogenic cells (ID50 0.02 and 0.2 Kg/ml, respectively), with 
a much larger range, reflecting the occurence of resistance [13] [figure 1.2]. 
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FIGURE U.a -006 .011 .03 
In vitro sensitivity of norma! bone marrow progenitor cells. Survival of CFU-GM (open and 
closed circles) and BFU-E (stars) (mean %±2 SD). Drug concentrations are in pg/ml. Modified 
with permission [13] 
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FIGURE I.2.b 
In vitro sensitivity of AML-CFU. Different symbols reflect different patients. Modified with 
permission [13] 
2.3 PHARMACOKINETICS IN ANIMALS 
Pharmacokinetic parameters of Ida and Dnr differed markedly, with 
different profiles found in mice [30], rabbits [31] as well in humans [32]. 
For example, the terminal half-lives were 23 hours (Ida) and 4.6 hours (Dnr) 
in mice, 4.4 hours (Ida) and <0.5 hours (Dnr) in rabbits, related to the 
extensive metabolism of Dnr [30,31], whereas in humans the terminal half-
life was 15-18 hours for both Ida and Dnr. The metabolic transformation of 
Ida was faster and more extensive in comparison with Dnr, especially after 
oral administration [32,33]. Ida concentrations in tumors were twice as high 
as the corresponding Dnr levels. Tissue drug accumulation of at least one 
log difference with plasma concentrations was noted for both Ida and Dnr 
14 
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[30,31] [figure 1.3]. Slightly higher Ida concentrations were found in kidney, 
lung, liver, spleen, tumor, and small intestine, with somewhat longer 
retention of Ida in these tissues compared with Dnr [26]. The toxicity 
spectrum differed per species. The kidney damage described with certain 
species, for example, has not been noted in humans. 
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Disappeareiìce curve of 15 mg/kg Dnr IV (DM) and 3 mg/kg IV and 7.5 mg/kg oral Ida (4DDM) 
in serum and tumor of mice. Solid lines represent Dnr or Ida, broken lines represent Dnrol or 
Idaol. Reprinted M'ith permission [31] 
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2.4 IN VIVO CYTOTOXICITY 
In several strains of experimental mouse leukemias, Ida was as 
effective or more active than Dnr [27]. The LD50 of Ida was four times 
lower than the LD50 of Dnr [28]. Activity of the metabolite Idaol in vivo 
was close to the cytotoxic effect of the parent drug [29]. However, orally 
administered Idaol was not as effective [29]. 
Among others, Ida and Dnr were compared in the DBA/2 mouse 
model inoculated with the ascitic P388 leukemia, in the BDF1 mice 
inoculated intraperitoneally (IP) or IV with L1210 leukemia cells, and in 
CH3/Hc mice inoculated with mammary carcinoma subcutaneously (SC). 
The drugs were administered IP, IV, or orally [28]. Drug effectiveness was 
based on the comparison of increase in median survival time with the 
control, or assessment of tumor growth. Consistently, Ida was approximately 
four times more toxic than Dnr, and at the maximum tolerated dose as active 
as Dnr [28]. For equal activity after oral administration, twice the IV dose 
was required. In a large series of 4-demethoxyanthracyclines investigated, 
the substitution of the 4-methoxyl group in the anthracycline molecule 
seemed to cause an increase in cytotoxicity, potency, and general toxicity 
without parallel increase in cardiotoxicity [28]. 
2.5 PHARMACOKINETICS IN HUMANS 
Patients with AML were treated with Dnr [33] or Ida [32], 
administered as three consecutive bolus injections, as infusions of different 
durations, or orally (Ida only), at equimyelotoxic dosages, (ie, Dnr 45 
mg/m7d IV and Ida 10 mg/m7d IV, or 30 mg/m7d orally on days l,2,and 3). 
The treatment further consisted of cytosine arabinoside 200 mg/m:/d IV on 
days 1 to 7, and vincristine 1 mg/m1 IV on day 2. Blood and bone marrow 
samples were collected at different times. Plasma and cells were separated 
and plasma and white cell drug concentrations were determined by HPLC 
[23]. Differences in pharmacokinetic behavior have been summarized in 
Table I [32,33]. 
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Table I. 
Differences in pharmacokinetic parameters of Ida ν Dur in humans 
Peak cone 
(ng/mlb) 
t'/zcc (mm) 
t!4ß (h) 
AUCp 
(mg.h/L) 
AUCm 
(mg.h/L) 
AUCm 
AUCpd 
Vd(L) 
Plasma 
IDA 
IV 
49 ± 
15 
0 3 ± 
0.2 
15± 
4 
0.5 ± 
0.1 
1.7± 
1.2 
3 
2250 
Orally 
11 ± 
13 
0.4 ± 
0.3 
12± 
4 
0.3 ± 
0.1 
2.1 ± 
0.3 
5 
DNR 
IV 
227 ± 
116 
0.3 ± 
0.1 
15± 
3 
1.6± 
0.5e 
6.8 ± 
13 
4 
2690 
Cells 
IDA 
IV 
9000 ± 
3450 
0.9 ± 
0.8 
18± 
8 
148 ± 
18 
121 ± 
33 
0.8 
Orally 
4150± 
1050 
0.9 ± 
1 
14± 
5 
170 ± 
2 
448 ± 
84 
3 
DNR 
IVa 
16810± 
2580 
0.3 ± 
0.2 
12± 
3 
610± 
25 e 
199 ± 
46 
0.3 
Abbrevalions ι'Λ, half-life, Vd, apparent volume of distribution 
a No DNR available for oral administration 
DIl has been assumed that 109 cells = 1 ml 
CIDA IV 10 mg/m2, IDA orally 30 mg/in2, DNR IV 45 mg/m2 
dAUCm/AUCp ratio of Area Under the Curve for the 13-OH-metabohle (m) over parent drug (p) 
Data from Spelh ci al [32,33] 
2 6 PLASMA PHARMACOKINETICS 
Peak Ida levels at five minutes after injection were approximately five 
times lower than peak Dnr levels (figures 1.4 and 1.5). The enormous 
cellular drug uptake is reflected in the large apparent volume of distribution 
of approximately 2,250 L for Ida, and 2,700 L for Dnr. Terminal half-lives 
were approximately 15 to 18 hours for Ida and Dnr. The 13-OH-metabolites 
17 
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Idaol and Dnrol were detected in plasma at the first sampling point (five 
minutes after injection), the concentrations exceeded the parent drug 
concentrations at approximately two to four hours (Ida) and 0.5 to 1 hour 
(Dnr) after injection, and increased at each consecutive administration 
[32,34]. 
( ng/inl ) 
10' 
10' 
M ^ — o -
0 2Λ ли 72 90 12Û M« loe )<J2 2'.6 
—» lime (Ijuril 
FIGURE 1.4 
Concentration-time curve of 
Ida (closed symbols) and the 
metabolite Idaol (open 
symbols) in plasma (circles) 
and in nucleated cells 
(squares). Ida 10 mg/m was 
administered as a rapid 
injection on three consecutive 
days. Reprinted with 
permission [32]. 
FIGURE 1.5 
Concentration-time curve of 
Dnr (closed symbols) and the 
metabolite Dnrol (open 
symbols) in plasma (circles) 
and in nucleated cells 
(squares). Dnr 45 mg/m was 
administered as a rapid 
injection on three consecutive 
days. Reprinted with 
permission [33]. 
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In case of long-term infusion (eg, three times daily, figures 1.6 and 
1.7), the peak plasma levels were reduced by a factor of 10 (Ida, Dnr), 
whereas the maximum 13-OH-metabolite concentrations were hardly 
influenced. In case of oral Ida ingestion (figure 1.8), the shape of the plasma 
concentration-time curve was close to that observed during a four-hour 
infusion (figure 1.9), with first plasma concentrations measured half an hour 
after ingestion, and maximum concentrations at four hours [32]. In contrast 
to the four-hour infusion, after oral ingestion Idaol concentrations markedly 
exceeded the Ida levels, due to the first-pass effect through the liver . 
Bioavailability was approximately 30%, as has been found by others 
[35,36]. The AUCm/AUCp (m, 13-OH-metabolite; p, parent drug) ratios in 
plasma were approximately 3 for both Ida IV and Dnr IV, and 5.7 for Ida 
orally. 
Figure 1.6 Figure 1.7 
FIGURE 1.6 
Concentration-time curve of Ida (closed symbols) and the metabolite Idaol (open symbols) in 
plasma (circles) and in nucleated cells (squares). Ida 10 mg/m was administered as a 72-hour 
infusion over three consecutive days. Reprinted with permission [32J. 
FIGURE 1.7 
Concentration-lime curve of Dnr (closed symbols) and the metabolite Dnrol (open symbols) in 
plasma (circles) and in nucleated cells (squares). Dnr 45 mg/m was administered as a 72-hour 
infusion over three consecutive days. Reprinted with permission [33]. 
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Figure 1.8 Figure 1.9 
J I L 
0 24 -ιβ 72 M ^ 2 0 144 Ι β β 192 216 
FIGURE 1.8 
Concentration-time curve of Ida (closed symbols) and the metabolite Idaol (open symbols) in 
plasma (circles) and tn nucleated cells (squares). Ida 30 mg/m was administered orally on three 
consecutive days. Reprinted with permission [32J. 
FIGURE 1.9 
Concentration-time curve of Ida (closed symbols) and the metabolite Idaol (open symbols) in 
plasma (circles) and in nucleated cells (squares). Ida 10 mg/m was administered as a 4-hour 
infusion on three consecutive days. Reprinted with permission [32]. 
2.7 CELLULAR PHARMACOKINETICS 
Like Dnr, Ida and Idaol were concentrated intracellular^' up to a factor 
300 times the plasma concentration. Differences in short-lasting (<5 
minutes) peak Ida and longer-lasting (one to two hours) peak Dnr cellular 
concentrations were observed, with rapid terminal half-life in cells of 12 to 
15 hours. There was no accumulation of Ida or Dnr during subsequent 
injections, 24 hours apart. On the other hand, a slight cellular Idaol (more 
than Dnrol) accumulation was noted on consecutive days, as well as during 
continuous infusion (figs 1.6 and 1.7) and oral ingestion (fig 1.8). The AUC 
of parent drug + metabolite (AUCp + AUCm) in cells differed for Ida orally, 
20 
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Ida IV, and Dnr IV, yet the clinical outcome in this small series of patients, 
as well as in larger series [37] remained comparable. The ratio of 
AUCm/AUCp in cells was always <1 after parenteral drug administration 
(0.8 Ida, 0.4 Dnr), but 3.5 for Ida orally. Because cytotoxicity of oral 
treatment was similar to that after IV treatment, this also points to the role of 
Idaol in the activity of Ida. 
In both Ida and Dnr, good correlations existed between cellular drug 
concentrations in peripheral blood cells and bone marrow cells. Ida has good 
clinical activity [35,37] especially in AML and relapsed or refractory 
leukemias [27] but limited effect in solid tumors [16,38]. The spectrum of 
Ida does not seem to be different from that of Dnr [16]. The claimed lack of 
cross-resistance needs to be confirmed [16]. Although in certain multidrug 
resistant cell lines cross-resistance to idarubicin is observed, the level of 
resistance to idarubicin has been reported to be less compared to 
doxorubicin or daunorubicin [39,40]. 
In conclusion, cellular and plasma pharmacokinetics of Ida and Dnr 
showed striking differences. Extrapolation of the pharmacokinetic findings 
to their clinical implications was not yet possible, due to the large 
interindividual variations and the lack of data relating in vivo observed 
cellular drug concentrations to their effect on selective eradication of 
clonogenic leukemia/tumor cells. Animal and human pharmacokinetics 
showed differences in half-lives, metabolism, and toxicity, which have been 
attributed, among other reasons, to differences in aldoketoreductase-
activities in animal and humans [30,31]. In vitro studies only partially 
predicted in vivo cellular pharmacokinetics, due to the lack of metabolism in 
vitro, and the relatively constant medium drug concentrations. Based on the 
above summarized (pharmacokinetic) data, Ida is as potent as Dnr for the 
treatment of leukemias at 25% of the Dnr dose. In selected cases, oral Ida 
might get a place in the therapeutic arsenal. 
3. DRUG RESISTANCE 
A major obstacle impeding the success of the anthracyclines is drug 
resistance. Several mechanisms of drug resistance have been proposed and 
characterized of which overexpression of the mdr-1 encoded P-glycoprotein 
21 
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is the most prominent representative [39]. Cells exhibiting resistance to 
doxorubicin are commonly cross-resistant to daunorubicin. Although in 
certain multidrug resistant cell lines cross-resistance to idarubicin is 
observed, the level of resistance to idarubicin has been reported to be less 
compared to doxorubicin or daunorubicin [40,41]. Drug resistance can be an 
innate or acquired property of the target cells involved. One manifestation of 
innate drug resistance is kinetic resistance which can involve reduced drug 
sensitivity due to the cell's proliferative state or different sensitivity between 
distinct phases of cell cycle. Both the proliferative state (17) and the cell 
cycle phase (12,13) have previously been shown to effect doxorubicin 
efficacy. 
Information on how cell proliferation parameters can effect drug treatment is 
important for more which may be occuring only in discrete phases during 
cell proliferation. If so, then knowledge concerning cell cycle kinetics 
becomes important for drug scheduling. Moreover, the rate of cell 
proliferation may be an important factor. For instance, normal bone marrow 
and intestine contain cells with a high rate of cell proliferation, and damage 
to these cells may be dose limiting for chemotherapy. 
Concepts related to the cell cycle are therefore not only of biological interest, 
but they are important also to understanding the interaction of drugs with 
tissues. This basic information is required for optimal application of 
chemotherapeutic agents. 
4. ΤΙΤΕ CELL CYCLE 
The first indications that cell proliferation involves more than just a 
continuous synthesis of DNA and subsequent cell division came with the 
demonstration that radio-labeled precursors of DNA are incorporated only 
into a discrete population of cells [2]. This result indicated that DNA 
synthesis takes place only in a specific period of the cell cycle, the S-phase. 
Experiments using approaches similar to these have led to a general model 
of cell proliferation shown in figure 1.10 [3]. 
22 
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FIGURE 1.10 
Model for cell proliferation , indicating the individual phases of the cell cycle and the 
relationship between proliferating and non-proliferating cells and the proces of cell death 
The period between mitosis (M), during which cell division takes 
place, and S-phase, during which DNA synthesis takes place, was 
designated as Gl phase. The period between S-phase and mitosis was 
designated G2 phase. Non-proliferating cells that retain the capacity to 
divide following an appropriate stimulus are arrested between the M and S-
phases and are referred to as GO cells. 
4 1 STUDY OF CELL KINETIC PARAMETERS 
A crude parameter of the overall rate of cell proliferation in a cell 
population is the labeling index (LI). The LI corresponds with the proportion 
of labeled cells in a cell population following a short exposure to tritiated 
thymidine (Ή-Thy). Being a DNA precursor, thymidine will be incorporated 
into DNA during S-phase. Subsequently, autoradiography can be used to 
detect the presence of the radio-active Ή-Thy in cellular DNA and thus to 
determine the LI. Determination of the mitotic-index (MI; number of 
mitotic figures) can provide similar information. However, since the 
duration of S-phase is longer than that of mitosis, labeled (S-phase) cells are 
more numerous and usually easier to recognize than mitotic figures, making 
LI preferable over MI. 
23 
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Thymidine labeling can also be used to estimate cell cycle time and 
duration of individual phases of the cell cycle but it requires more complex 
labeling studies such as the percent-labeled-mitoses (PLM) method [4]. In 
the PLM method, sequential samples are taken at intervals after a single 
exposure to Ή-Thy. Cells in mitosis may be recognized under the 
microscope and the proportion of mitoses that is labeled is estimated from 
autoradiographs prepared from these samples. In an ideal cell population 
with constant phase duration, the passage of cells that were initially labeled 
in S-phase through the mitotic phase leads to waves of labeled mitoses from 
which the width corresponds to the duration of S-phase and separation 
corresponds to the cell cycle time. A necessary assumption one has to make 
with determining cell-cycle parameters by PLM curves is that these 
parameters do not change rapidly with time, and are not altered by 
incorporation of the radiolabeled thymidine. An important consideration 
when using the PLM method is the bias by the more rapidly proliferating 
cells. Faster proliferating cells will pass through mitosis more frequently and 
during analysis these cells cannot be separated from non-proliferating cells 
or cells with cell cycle times much longer than the mean [5]. 
In bone marrow there is evidence for a limited population of stem cells 
and committed progenitors which are defined by their potential for 
regenerating all or part of the hematopoietic cell population. The existence 
of stem cells was demonstrated through functional clonogenic assays that 
showed their proliferative potential by the formation of colonies. 
Information analogous to the LI may be obtained for stem cells by 
comparing colony formation by untreated cells and by cells treated with 
high-specific-activity 'H-thymidine (thymidine suicide method)[12]. Those 
cells that are synthesizing DNA at the time of thymidine administration will 
be killed by radiation damage from the high dose of tritium, leading to a 
reduction in the number of colonies. 
The study of cell kinetics has been facilitated by the use of flow 
cytometry to determine cellular DNA content. In DNA flow cytometry, 
typically a single cell suspension is prepared and cells are stained with a 
fluorescent dye whose binding is proportional to DNA content. Cells are 
then directed in a single file through a laser beam to excite the DNA-specific 
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dye, and the fluorescence emission is collected and displayed as a 
fluorescence distribution. Thus a static, temporary reflection of the cell cycle 
phase distribution of the cell population is obtained. An important 
development towards kinetic flow cytometric studies, is the use of 
nonradiocative DNA precursors which like thymidine are incorporated into 
the newly synthesized DNA of S-phase cells, and which may be recognized 
by flow cytometry [6-9]. Suitable precursors include 5-bromodeoxyuridine 
(BrdUrd) and 5-iododeoxyuridine (IdUrd), which can be recognized in 
denatured DNA using monoclonal antibodies [10]. Determination of the 
proportion of cells that incorporate one of these precursors provides an 
estimate of LI. Short-term exposure to BrdUrd or IdUrd leads to the labeling 
of a cohort of cells that is originally in S-phase and which then moves 
through the cell cycle. Application of a DNA stain (eg propidium iodide) in 
combination with monoclonal antibodies visualizing the incorporated 
halogenated precursor used with 2 parameter flow cytometry thus allows the 
passage of this cohort of cells to be followed as it traverses through the cell 
cycle [11]. Despite their potential for cell-cycle analysis, all of these 
methods have similar limitations to those of the PLM method, the most 
important of which is the bias to give information about the most rapidly 
proliferating cells in a population. 
Many investigators have proposed that measurement of cell kinetic 
parameters following initial treatment might be used as a guide to 
optimization of subsequent scheduling of phase-specific anticancer drugs. 
The LI and flow cytometry have been used most frequently as a guide to 
drug scheduling. Unfortunately, the value of the thus obtained information is 
limited because usually no distinction is made between the important 
surviving clonogenic cells, and the greater number of cells that were arrested 
by initial treatment and that may remain intact for some time prior to their 
lysis. Improved methods for studying the proliferative state of clonogenic 
cells are essential if cell proliferation is to be studied after cancer treatment 
and used as a guide to the scheduling of phase-specific anticancer drugs. 
4.2 INDIVIDUAL COLONY FORMATION ASSAY 
A commonly applied method to evaluate the clonogenic potential of a 
cell is the colony formation assay, wherein immobilized cells are allowed to 
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proliferate and growth is quantified by the enumeration of progeny. Time-
lapse cinematographic approaches and time-lapse video approaches have 
been used to determine the growth rate of individual cells in colony 
formation assays through direct observation. These approaches however 
permit collection of data for relatively small numbers of cells. Recently, a 
method was developed using image analysis to track the growth of 
individual colonies in semi-solid medium. This method, which was termed 
the individual colony formation assay (iCFA), represented the first occasion 
in which the proliferative behavior (including growth rate) of large numbers 
of individual clonogenic cells could be studied kinetically. 
5. AIM OF TIIÏS STUDY 
The aim of this study is to determine how cell cycle kinetic parameters 
effect efficacy of commonly used anthracyclines at clinically relevant drug 
concentrations and how cell cycle kinetics are effected by exposure to these 
drugs. 
Actively cycling cells progress from the Gl-phase through S-phase to 
the G2/M-phase after which cell division takes place and each of the 
daughter cells commences their cell cycle starting from Gl. Chapter 2 
describes how the position in the cell cycle effects drug uptake, retention 
and toxicity. However, cells can also be in a non-cycling state (GO). In order 
to determine how the proliferative state effects anthracycline toxicity, 
sensitivity of human lymphocytes and human CFU-GM to doxorubicin 
exposure before and after proliferation induction or enhancement of 
proliferation are studied in Chapter 3. Chapter 4 compares the proliferation-
dependent toxicity of doxorubicin and idarubicin towards human bone 
marrow progenitors (CFU-GM and CFU-L) at clinically relevant drug 
concentrations. In Chapter 5 kinetic cell cycle changes following exposure 
to doxorubicin are described utilizing human leukemic cell lines (Molt-4, 
K562) and two-parameter IdUrd/propidium iodide flow cytometry. Chapter 
6 compares the changes in growth characteristics of individual colonies 
derived from hematopoietic cells (K562) which survived exposure to 
doxorubicin, daunorubicin, and idarubicin utilizing the iCFA technique. The 
results of the studies described in this thesis are summarized and discussed 
in Chapter 7. 
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ABSTRACT 
Exponentially growing Molt-4 cells were separated by means of counterflow 
centrifugati on into fractions enriched for cells in early Gl, late Gl, S, or 
G2+M phase of the cell cycle. Subsequently, cells were exposed for 2h to 
Idarubicin (Ida, 0.02 - 0.15 μg/ml), Daunorubicin (Dnr, 0.1 - 0.75 ц§/т1), or 
Doxorubicin (Dox, 0.1 - 0.75 μg/ml). Drug uptake, measured by flow 
cytometry, increased progressively with cell cycle traverse from early Gl- to 
M-phase. The relative fraction of drug lost following an extensive wash 
procedure was 72% in case of Ida and 23% for Dnr and Dox and was 
independent of the cell cycle phase. Inhibition of DNA synthesis was 
determined by qualitative flow cytometric analysis of 5-iodo-2'-deoxyuridine 
(IdUrd) incorporation into DNA. The three drugs showed a similar gradual 
increase of inhibition of DNA synthesis from Gl to G2+M phase 
demonstrating that cell cycle phase dependency of drug toxicity applies to 
all three anthracyclines studied. 
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INTRODUCTION 
The anthracyclines form a large family of drugs from which several 
members have been successfully used in cancer chemotherapy. Although 
many derivatives have been synthesized over the years, doxorubicin and 
daunorubicin still remain to be the most prominent representatives in 
clinical application with Idarubicin now emerging as an important 
alternative. A major obstacle impeding the success of the anthracyclines is 
drug resistance which can be an innate or acquired property of the target 
cells involved. One manifestation of innate drug resistance is kinetic 
resistance which can involve altered drug sensitivity due to the cell's 
proliferative state or different sensitivity between distinct phases of cell 
cycle. Both the proliferative state (17) and the cell cycle phase (12,13) have 
been shown to effect doxorubicin efficacy. This study was conducted to 
compare the cell cycle phase dependent efficacy of Dnr and Ida with that of 
Dox. 
On a chemical basis, the differences between Doxorubicin (Dox), 
Daunorubicin (Dnr), and Idarubicin (Ida) are relatively small. Dox differs 
from Dnr by one hydroxylgroup while Ida only differs from Dnr by the lack 
of one methoxyl group. These small differences in chemical structure 
resulted however in significant differences in plasma and cellular 
pharmacokinetics (1,2). At equimolar dosages, the choice of Dox or Dnr 
does not effect the remission induction rate or duration of disease-free 
survival (3). In vitro however, the toxicity of Dnr toward hematopoietic cells 
is greater compared to Dox (4-6). Ida is more potent than Dox and Dnr, 
achieving comparable toxicities than Dnr at 25% of the equimolar dose 
(7-11). 
Studies related to cell cycle phase dependent uptake and toxicity of 
anthracyclines were initiated two decades ago and were reviewed in 1986 by 
Barranco (12). The majority of the early studies used cell synchronization 
methods like harvesting mitotic cells following colcemid treatment. A 
drawback of these methods is that the methods themselves interfere with cell 
kinetics. Counterflow centrifugation is a method that allows separation of 
exponentially growing synchronous cell populations by using cell size and 
density as discriminative parameter. This method is able to generate large 
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numbers of synchronized cells in a relatively short period of time and more 
importantly, without exposure to a synchrony-inducing agent. Recently, 
counterflow centrifugation was used to investigate the cell cycle dependent 
toxicity of Dox (13). The present study investigates cell cycle phase 
dependent drug uptake and toxicity of Ida and Dnr at clinically achievable 
plasma concentrations, using synchronized cell populations which were 
obtained with counterflow centrifugation and compares these results with 
the previously obtained data for Dox. 
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MATERIALS AND METHODS 
Cell line and cell culture conditions 
The human T-ALL cell line Molt-4 was maintained at exponential growth in 
RPMI 1640 medium (Flow Laboratories, Irvine, Scotland) supplemented 
with 10 % (v/v) heat inactivated (HI; 30 min, 56 °C) fetal calf serum (FCS) 
(Gibco, Grand Island, NY, USA), 100 ц^т і Streptomycin, 100 IU/ml 
Penicillin and 2 mM L-glutamine (Flow laboratories, Irvine, Scotland), 
which will be referred to as 'supplemented RPMI 1640 medium'. Cells were 
cultured in a 5% C02- 95% air, fully humidified atmosphere at 37°C. Cell 
cultures were routinely checked for absence of Mycoplasma infection. 
Counterflow centrifugation. 
Separation of cells was achieved using a multi-chamber counterflow 
centrifugation system (Curamée 3000, Dijkstra Vereenigde, Amsterdam, 
The Netherlands). In short: At constant flow rate and rotation speed, cells 
were introduced into the centrifugation chambers where they aligned 
according to their size and density. Subsequently, the cells were forced to 
exit the chambers by step-wise decrease of the rotation speed at constant 
flow rate. Cells were collected in 10-15 fractions. The DNA content of each 
fraction was determined by propidium iodide staining and flow cytometry as 
described previously (14) after which the fractions were pooled to obtain 
fractions enriched for cells in early Gl, late Gl, S, and G2+M phase based 
on DNA content. 
Drug exposure 
Ida, Dox (Farmitalia Carlo Erba, Milan, Italy), or Dnr (Rhone Poulenc, 
France), Milan, Italy) were added to the various cell fractions to the desired 
final drug concentrations (Ida 0.02 - 0.15 ц§/т1, Dnr 0.1 - 0.75 ng/ml, Dox 
0.1 - 0.75 μg/ml) from a frozen stock made in phosphate buffered saline 
(PBS). Drug incubations were performed at cell density of 1 χ IO6 cells/ml 
for 2 h in a shaking waterbath at 37 °C. 
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Quantitative flow cytometric determination of cellular anthracycline 
concentrations. 
A linear relationship between the average cellular fluorescence intensity and 
intracellular anthracycline concentrations has been demonstrated (15,16). 
Flow cytometry was performed as described previously (16) using a System 
ЗОН Cytofluorograf (Ortho Diagnostic Systems, Westwood, MA, USA). 
FCM analysis was performed immediately following drug-exposure and 
after a three-step wash procedure with PBS + 1% HI FCS which followed 
the drug exposure. The fluorescence data are expressed in mean arbitrary 
fluorescence units and are corrected for autofluorescence by subtracting the 
fluorescence of control cells (not drug-exposed). The FCM data regarding 
the anthracycline-related fluorescence intensities of individual cells were 
recorded in list mode together with their forward scatter values (FSC, 
parameter for cell volume). This provided the opportunity to determine the 
relationship between cellular drug content and drug concentration by 
dividing individual fluorescence intensities by corresponding FSC values as 
described previously (18). This method was applied to determine if cell 
cycle phase related changes in cell volume effected measurements of drug 
content. 
Flow cytometric evaluation of DNA synthesis 
Following drug exposure and wash procedures drug effect on active DNA 
synthesis was evaluated by incubating cells (10^/ml, 5% C02-95% air, fully 
humidified atmosphere at 37°C) for 24 h in supplemented RPMI 1640 
medium in the presence of 5 μΜ IdUrd. Subsequently, cells were fixed and 
analyzed for IdUrd incorporation as described previously (17). 
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RESULTS 
Cell synchronization 
The cellular DNA content of each of the 10-15 fractions collected during 
counterflow centrifugation was analyzed by FCM. Subsequently, fractions 
were pooled to obtain fractions enriched for cells in early Gl phase, late Gl 
phase, S-phase, and G2+M phase based on DNA content. Representative 
DNA distributions of the thus obtained pooled fractions are displayed in 
figure 2.1 and summarized in table I. The purest population obtained was 
the early Gl phase ( >96% Gl DNA content). The progress through the cell 
cycle with each fraction is clear from figure 2.1 by the continuous increase 
of the DNA content. However, due to the stringency of dividing the cell 
cycle in three compartments, the differences between early and late Gl 
phase, and S and G2+M phase are less obvious from table I and are 
represented only by subtle changes in percentages of the adjacent cell cycle 
compartments. 
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FIGURE 2.1 
DNA disributions of original (loaded) sample and pooled fractions following counterflow 
centrifugation 
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Table 1. Cell cycle phase distribution of cell fractions pooled after counter/low centrifugation. 
loaded sample 
early Gl phase 
late Gl phase 
S phase 
G2+M phase 
Gl 
52% 
9 7 % 
89% 
16% 
8% 
S 
4 4 % 
3 % 
1 1 % 
7 5 % 
7 5 % 
G2+M 
4 % 
0 % 
0 % 
9 % 
17% 
Drug uptake in relation to cell cycle phase 
The cellular drug uptake of all three drugs slightly increased with 
progression from early Gl to the G2+M phase. Correction of cellular 
fluorescence for cell size, by dividing the individual cell fluorescence values 
by their forward scatter (FSC) value (18,19), had no significant influence on 
the observed cell cycle phase dependent differences. As an example, figure 
2.2 shows the cellular drug concentrations with and without correction for 
size for cells exposed to Dox. Similar patterns were observed with Dnr and 
Ida before and after the wash procedures. Since drug uptake was gradually 
increasing from Gl to G2+M phase, the cell cycle dependent differences in 
cellular drug concentrations (arbitrary fluorescence units) are summarized 
by calculating the ratios of cellular drug concentration for the two extremes 
(early Gl and G2+M). In case of Dox, these ratios were 1.9 ± 0.3 (mean ± 
SD, N=12), for Dnr 1.3 ± 0.2, and 1.4 ± 0.2 for Ida. 
Following the wash procedure cellular drug concentrations decreased most 
notably in case of Ida. The average decrease of cellular drug concentrations 
after, versus before the wash procedure was 1.3 ± 0.2 fold (mean ± SD, 
N=6) for Dox, 1.3 ± 0.1 fold for Dnr, and 3.6 ± 0.4 fold for Ida. No cell 
cycle phase dependent differences in decrease of cellular drug content before 
or after the wash steps were observed. Figure 2.3 shows examples of the 
drug uptake and retention studies for each of the three drugs and each of the 
drug concentrations used. 
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FIGURE 2 2 
Cellular Dox concentrations 
determined flow cytometri-
cally without correction for 
cell size (panel A) and 
following correction for cell 
size by dividing individual 
cell fluorescence values by 
their FSC values (Panel B). 
Cells were exposed for 2h to 
0 1 μg/m¡ (open circles), 0.2 
fjg/ml (closed circles), 0.3 
μg/m¡ (open triangles), 0 4 
μξ/rnl (closed triangles), 0 5 
μg/m¡ (open squares), 0.75 
μg/m¡ (closed squares) 
FIGURE 2 3 
Drug uptake measured 
immediately following 2h 
exposure to Dox (panel A) 
and retention measured 
following cell wash pro-
cedures (panel D). Legends 
to drug concentrations are 
the same as in figure 2.2. Dnr 
uptake and reten-tion are 
shown m panels В and E, 
respectively Legends to drug 
concentra-tions are the same 
as m figure 2.2. Ida uptake 
and retention are shown m 
panels С and F, respectively, 
0.02 μg/ml (open circles), 
0.04 pg/ml (closed circles), 
0 06 μξ/ml (open triangles), 
0.08 pg/ml (closed triangles), 
0.1 μg/ml (open squares), 
0 15 μg/ml (closed squares) 
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Drug toxicity in relation to cell cycle phase 
Toxicity was studied by flow cytometric measurement of inhibition of DNA 
synthesis. Cells showing active DNA synthesis were detected by 
incorporation of 5-iodo-2'-deoxyuridine (IdUrd) into DNA during a 24 h 
continuous IdUrd exposure. This previously applied method (17) 
discriminates DNA synthesizing cells qualitatively from cells which do not 
display active DNA synthesis. It is important to note that the IdUrd labeling 
is used qualitatively rather than quantitatively because of previous reports 
which demonstrated slow down of cell cycle traverse following 
anthracycline exposure (20,21). It is conceivable that growth slow down 
effects DNA synthesis rate and thus the quantitative but not the qualitative 
labeling with IdUrd. 
With progression through the cell cycle from early Gl towards G2+M phase, 
all three drugs demonstrated a gradual increase of inhibition of DNA 
synthesis. For each drug and each cell cycle phase the drug concentration 
which inhibited DNA synthesis in 50 % of the cells compared to the controls 
was determined (IC50). To summarize the increase of toxicity, the IC50's for 
each drug for the two extremes (early Gl and G2+M cells) were determined. 
The IC50 for Dox for early Gl cells was 0.5 μg/ml versus 0.4 μg/ml for 
G2+M cells. For Dnr, the IC50 changed from 0.3 to 0.2 μg/ml while for Ida 
it changed from 0.09 to 0.03 μg/ml. Although the shifts in IC50's are small, 
the cell cycle dependent increase of drug toxicity was consistently observed 
for each drug and each drug concentration. This is clearly demonstrated in 
figure 2.4 where the toxicity is shown for each drug and for each drug 
concentration separately. 
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FIGURE 2.4 
Cell cycle dependent drug 
toxicity for Dox (panel A), 
Dnr (panel B), and Ida 
(panel C). Legends to drug 
concentrations are the same 
as figure 2.3. 
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DISCUSSION 
The observation that Dox toxicity increases as cells progress from Gl to 
G2+M phase is in good agreement with previous reports (12,13) with the 
exception that usually the late S- phase has been characterized to be the 
most sensitive cell cycle phase. The discrepancy between late S-phase and 
G2+M phase is inherent to the gradual transition of the various cell cycle 
phases in relation to the cellular DNA content. Obviously DNA content is 
related to the position in the cell cycle but transition from one phase to the 
other cannot be pinpointed to a particular DNA content. Thus, in the event 
of cell cycle phases being distinguished based only on DNA content, unless 
additional parameters are included, it might be more correct not to 
distinguish late S-phase cells from G2+M phase cells. Moreover, the purity 
of the cell populations should be considered. The cell populations used in 
the present study were enriched for particular cell cycle phases and they are 
not pure cell populations. The virtues of using counterflow centrifugation to 
obtain cell fractions enriched for particular cell cycle phases are that those 
fractions are obtained without any synchrony-inducing agent and that the 
fractions are obtained simultaneously from the same exponentially growing 
cell population. However, a lack of purity of the G2+M phase fraction in 
particular is a compromise we choosed to make by pooling several fractions 
in order to obtain large enough populations of each cell cycle phase to 
perform all the studies involved. Therefore, the cell populations enriched for 
cells in G2+M phase were considerably 'contaminated' with cells in (late) 
S-phase. 
The cell cycle phase dependent toxicity of Ida and Dnr was very similar 
to that observed for Dox. For all three drugs, the increase in drug toxicity 
was accompanied by an increase in cellular drug uptake which could not be 
attributed only to increase of cell volume. Considering the degree of the 
increase (1.3-1.9 fold), the increase in cellular drug concentrations could be 
related to increase in DNA content and the accesibility of the DNA for the 
intercalating agents. For all three drugs, the decrease in cellular drug 
concentrations as a result of extensive washing of the cells following drug 
exposure was independent of the cell cycle phase. There was however, a 
considerable difference between the loss measured for Dox and Dnr (1.3 
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fold) compared to that of Ida (3.6 fold). Structure-activity relationships 
indicate that structural features determine the lipid solubility of the drugs 
which is inversely related to cellular drug uptake (23,24) and (tight) binding 
to DNA (22). Since Ida is more lipophylic than Dox (Dnr shows 
intermediate lipophilicity), relatively less Ida might be tightly associated 
with the DNA explaining the greater loss of intracellular drug following 
wash. 
In conclusion, these studies demonstrate that drug uptake and inhibition 
of DNA synthesis are effected by the cell cycle phase in a similar way for 
the three anthracycline derivatives studied. Drug retention of Dox and Dnr is 
greater than for Ida but the fraction retained is independent of the cell cycle 
phase. Thus, with regard to the cell cycle phase, the data show that there is 
no apparent rationale for the prefered use of one drug over the other to 
overcome this form of innate drug resistance. Recently, modulation of cell 
cycle phase dependent efficacy of Dox by novobiocin was reported (13). 
Further investigation to determine whether similar modulation could also be 
achieved for Dnr and Ida would be of interest to complete the comparison 
between these drugs regarding this facet of their mechanisms of action. 
Additional studies to determine how the proliferative state effects the 
efficacies of these drugs have been initiated (17) and are currently ongoing 
in this laboratory. So far, it was demonstrated that dox toxicity could be 
augmented by enhancement of the proliferative state of hematopoietic cells 
(17). It is anticipated that these comparative data may ultimately lead to 
rationales of the prefered use of particular drug combinations to circumvent 
the unwanted effects of kinetic resistance. 
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Chapter 3: Cell Proliferation and Doxorubicin Toxicity 
ABSTRACT 
The relation between the proliferative state of normal human hematopoietic 
cells and their sensitivity to doxorubicin was studied. T-lymphocyles were 
stimulated with phytohaemagglutinin / interleukin-2 before or after a 2 h 
exposure to doxorubicin (range 0-2 μg/ml). The doxorubicin concentration 
which inhibited DNA synthesis in 50% of the lymphocytes, measured 
qualitatively with 5-iodo-2'-deoxyuridine incorporation, was significantly 
lower (factor 2.5) in case of drug exposure of stimulated lymphocytes 
compared to non-stimulated lymphocytes. These proliferation-dependent 
differences were not related to differences in cellular drug concentrations as 
was determined with flow cytometry. 
Bone marrow cells were stimulated for 2 days with human placenta 
conditioned medium before or after exposure to doxorubicin (range 0 - 2 μ 
g/ml), after which they were cultured in a bone marrow clonogenic assay. In 
analogy with the lymphocyte experiments, proliferation-dependent 
differences in drug sensitivity were found. The drug concentration which 
inhibited the growth of granulocyte/macrophage colonies (CFU-GM) to 50% 
appeared significantly lower (factor 3.4) with drug exposure of stimulated 
bone marrow cells compared to non-stimulated bone marrow cells. 
The relative insensitivity to doxorubicin of quiescent, but potentially 
proliferative cells might explain the recovery of hematopoiesis after 
doxorubicin induced bone marrow hypoplasia. 
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INTRODUCTION 
An undesirable side-effect of chemotherapy is the inhibition of normal 
hematopoiesis resulting in secondary pancytopenia. However, the inhibition 
is generally transitory and regeneration of the bone marrow occurs with 
time. 
The transit time of myeloid cells from the mitotic compartment to the 
circulating blood is approximately 14 days [1]. The same time period of 
10-14 days is also observed for mature white blood cells to appear in the 
circulation after bone marrow ablative therapy, followed by allogeneic bone 
marrow transplantation [2]. The leucocyte nadir after doxorubicin 
monotherapy is approximately 14 days [3]. It seems, therefore, that after 
doxorubicin monotherapy, myelopoiesis restarts within a few days. It has 
been demonstrated, however, that considerable amounts of doxorubicin 
remain present in the nucleated bone marrow cells for several days after 
exposure [4,5,6]. Obviously, hematopoietic clonogenic cells escape from the 
cytotoxic effect of doxorubicin which may be related to a drug-insensitive 
quiescent state at the time of doxorubicin exposure [7,8,9]. The concept of 
doxorubicin toxicity proliferation dependency is well established from cell 
lines [10,11]. The use of cell lines in these settings may raise some doubts 
concerning the comparability with the in vivo situation. The present study 
documents that the proliferation dependent toxicity of doxorubicin also 
holds for human hematopoietic cells. The sensitivity to doxorubicin of 
intrinsically non-proliferating peripheral blood lymphocytes and non-
stimulated bone marrow CFU-GM cells is compared with the sensitivity of 
their stimulated counterparts. 
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MATERIALS AND METHODS 
Blood and bone marrow sampling and isolation of nucleated cells 
After informed consent, venous blood of healthy volunteers was drawn in 
heparinized syringes. The bulk of red cells and granulocytes were removed 
by density gradient separation with Ficoll-Hypaque (Pharmacia, Uppsala, 
Sweden). The composition of the interphase was determined by flow cyto­
metric immunotyping with monoclonal antibodies OKT-3 (anti-CD3), OKT-
11 (anti-CD2), (Ortho Diagnostic Systems, NJ, USA), B4 (anti-CD 19), Bl 
(anti-CD20), MY-4 (anti-CDwH) (Coulter Immunology, Fl, USA). 
Interphase cells were washed twice with glucose phosphate buffer (134 raM 
NaCl, 5.4 mM KCl, 1.4 mM Na2HP04, 3.3 mM KH2PO4. 5.1 mM glucose) 
('GP buffer1) + 1% (v/v) fetal bovine serum (FBS, Gibco, Paisley, Scotland), 
GP buffer + 1% (v/v) FBS and resuspended in RPMI 1640 (Flow Labora­
tories, Irvine, Scotland) supplemented with 10% FBS, 100 IU/ml penicillin, 
100 μg/ml streptomycin and 2 mM L-glutamine (Flow laboratories, Irvine, 
Scotland), which is referred to as 'Growth Medium'. 
Normal sternal bone marrow aspirates were obtained from cardiac surgery 
patients after informed consent. The aspirates were collected in acid citrate 
dextrose (ACD-A, formula-A, pH 7.4). 
The bulk of red cells and mature granulocytes were removed by density 
gradient separation with Percoli (density 1.085 g/ml, pH 7.4, 300 mOsm/kg, 
Pharmacia LKB, Uppsala, Sweden). Interphase cells were collected, washed 
twice with GP buffer + 1% (v/v) FBS and resuspended in Growth Medium. 
Drug exposure and cell culture 
Prior to drug exposure, cell suspensions were preincubated in a shaking 
waterbath (37°C, 0.5 h). Doxorubicin (Roger Bellon, Neuilly sur Seine, 
France) was added to the cell suspensions from a frozen (-20 °C) stock 
prepared in phosphate buffered saline (PBS) to arrive at the final 
concentrations as indicated with each experiment. 
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Lymphocytes (10° cells/ml) were incubated with 0, 0.1, 0.2, 0.3, 0.4, 0.5, 
0.7, 1.0, or 2.0 μg doxorubicin/ml for 2 h in a shaking waterbath at 37°C. 
Incubations were stopped by washing the cells twice with PBS + 1% (v/v) 
FBS. Subsequently, the cells were stimulated by resuspending them (at 105 
cells/ml) in Growth Medium to which 5 μg/ml phytohaemagglutinin 
(Wellcome, Dartford, UK) and 20% (v/v) Lymphocult (IL-2, Biotest AG, 
Frankfurt Am Main, FGR) (Stimulation Medium A) was added. Cells were 
cultured in 16 χ 125 mm polystyrene, round bottomed tissue culture tubes 
(Becton Dickinson, NJ, USA) at 37°C, 5% CO2 in a fully humidified 
atmosphere for three days until determination of the number of DNA 
synthesizing cells as described later. 
Proliferation activity of lymphocytes, as determined with [3H]Thymidine 
incorporation, peaked after 2-3 days incubation in Stimulation medium A 
(data not shown). Therefore, drug exposure of stimulated lymphocytes was 
performed following a preincubation period (at 10^ cells/ml) of two days in 
Stimulation Medium A. The procedures for the subsequent drug exposure 
were the same as in case of the non-stimulated lymphocytes. 
Following the wash procedure, the cells were resuspended in Stimulation 
Medium A (10^ cells/ml) and cultured for one additional day until 
determination of the number of DNA synthesizing cells as described later. 
Culture conditions were the same as described above. 
Bone marrow cells were suspended in Growth Medium (10^ cells/ml). 
Doxorubicin was added from a stock to a final concentration of 0, 0.1, 0.2, 
0.3, 0.4, 0.5, 0.7, 1.0, and 2.0 μg/ml. Incubations were stopped by washing 
the cells twice with PBS + 1 % (v/v) FBS. Subsequently, cells were 
stimulated by resuspending them (at 10* cells/ml) in Growth Medium to 
which 5% (v/v) Human Placenta Conditioned Medium (HPCM) as 
described by Verma et al [12] was added ('Stimulation Medium B'). Cells 
were cultured for two days in tissue culture tubes at 37°C, 5% CO2 in a 
fully humidified atmosphere before they were plated in clonogenic assay. 
Stimulated bone marrow cells were obtained by preincubating the cells (10* 
cells/ml) in Stimulation Medium В for two days. Doxorubicin exposure and 
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wash procedures were then performed as described above. After the wash 
procedure, the cells were plated in clonogenic assay. 
Quantitative flow cytometric determination of cellular doxorubicin in 
lymphocytes 
A linear relationship between the average cellular fluorescence intensity and 
cellular doxorubicin concentration has been demonstrated [13,14]. Flow 
cytometry (FCM) was performed with a System ЗОН Cytofluorograf (Ortho 
Diagnostic Systems, Wes:wood, MA, USA) as described earlier [14]. The 
flow cytometer was calibrated with standard 1.9 μτη fluorescent 
microspheres (Fluoresbrite, Polysciences, Warrington, PA, USA). FCM 
analysis was performed after the two-step wash procedure that followed the 
drug exposure. The fluorescence data are expressed in mean arbitrary 
fluorescence units and are corrected for autofluorescence by subtracting the 
fluorescence of control cells (not exposed to doxorubicin). 
Determination of the number of DNA synthesizing lymphocytes 
Three days after the initial stimulation of the lymphocytes, the number of 
DNA synthesizing cells was determined. IdUrd (Sigma, St. Louis, USA) 
from a frozen stock in PBS, was added to the cultures to a final concentra­
tion of 5 μΜ, and the cells were cultured for an additional 24 h. 
Subsequently, cells were washed twice with cold (4°C) PBS + 1% (v/v) FBS 
+ EDTA (0.5 mM). Aliquots of 10° cells/sample were fixed in ice-cold 75% 
(v/v) ethanol/PBS and stored at -20 °C until measurement. The stored 
samples were handled according to the method described by Van Εφ et al 
[15]. In short: fixed cells were washed with PBS and DNA denaturation was 
performed by 30 min incubation at room temperature with 1 ml pepsin/HCL 
(1 mg pepsin (Serva, Heidelberg, FGR) /ml 2 N HCL). Neutralization was 
accomplished by addition of 1 ml sodium tetraborate (final concentration 0.1 
M). Cells were then washed twice with PBS, labeled with 20 μΐ/ IO6 cells 
FITC-conjugated anti-BrdUrd (Becton Dickinson) which is cross reactive 
with IdUrd, and counterstáined for DNA with 25 μg/ml PI (Sigma, St. Louis, 
USA) in PBS. 
58 
Chapter 3: Cell Proliferation and Doxorubicin Toxicity 
Cells stained with FITC and PI were measured with a System ЗОН 
Cytofluorograf (Ortho Diagnostic Systems, Westwood, MA, USA). The 488-
nm line of a 5-Watt Argon ion laser was used for excitation. A 580- nm di-
chroic mirror, a high-pass filter RG630 nm ifor red), and a bandpass filter 
515/530 nm (for green) were used. Five χ IO** cells were measured at a flow 
rate of approximately 100 cells per second. The area of the green 
fluorescence signal and both area and peak value of the red fluorescence 
signal were recorded in list mode. The ratio area:peak discriminates between 
artifacts due to doublets of diploid cells and real single tetraploid (or late S) 
cells, when intact cells are used. The data were stored on and analyzed with 
a PDP11/34 computer (Digital Equipment, Galway, Ireland). 
Two representative examples of analysis for IdUrd incorporation are shown 
in Figure 3.1. 
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Figure 3. I A. IdUrd incorporation (24 h exposure) (green fluorescence, ordinate) of PHA/IL-2 
stimulated control lymphocytes plotted against the DNA distribution (red fluorescence, 
abscissa). The marked box reflects the threshold for discrimination of cells that had or had not 
incorporated IdUrd during DNA synthesis. The threshold was determined by the background 
fluorescence of IdUrd non-labeled cells. 
Figure 3. IB. IdUrd incorporation (24 h exposure) of lymphocytes exposed to doxorubicin (0.5 
ug/ml, 2 h) and subsequently stimulated for 2 days by PHA/IL-2. Threshold setting as in I A. 
Figure 3.1a shows an example of control cells (not exposed to doxorubicin). 
IdUrd incorporation (green fluorescence) is plotted against the DNA 
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distribution (red fluorescence). Every cell synthesizing DNA during the 24 h 
IdUrd exposure will have been labeled. Threshold setting was determined by 
analysis of background green fluorescence of control cells not labeled with 
IdUrd. Figure 3.1 В shows the IdUrd incorporation of lymphocytes which 
have been exposed to doxorubicin (0.5 μg/ml, 2 h) prior to stimulation with 
PHA/IL-2. This demonstrates that doxorubicin exposure increases the 
amount of non-labeled cells (not capable of DNA synthesis), especially in 
the G2+M compartment of the cell cycle. 
CFU-GM clonogenic assay 
CFU-GM cultures were performed in duplicate in 35 mm Petri dishes 
(Costar, Cambridge, Mass., USA) as described previously [16]. In brief: 
each dish contained 2 ml of a cell suspension (10* cells/ml) in Iscove's 
medium (Flow Laboratories, Irvine, Scotland) supplemented with 20% (v/v) 
FBS, 5% (v/v) HPCM as described by Verma et al. [12] and 0.3% (w/v) 
bacto agar (Difco, Detroit, MI, USA). The cultures were incubated at 37°C 
in a fully humidified atmosphere of 5% CO2 in air. After 14 days, cell 
aggregates consisting of 50 cells or more were scored as colonies. 
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RESULTS 
Enrichment for T-Iymphocytes 
A typical composition of the density gradient interphase from peripheral 
blood as determined by flow cytometric immunotyping was : 80 % T-lym-
phocytes (CD2+), 8% B-lymphocytes (CD 19+), 14% myelomonocytic cells 
(CDwl4+). In all cases the interphase consisted of 80 % or more T-lympho-
cytes. 
Lymphocytes stimulation efficiency 
Stimulation efficiency (the % of DNA synthesizing cells after stimulation 
with PHA/IL-2) could be monitored by evaluating the IdUrd incorporation 
of the control lymphocytes population (Figure ЗЛА). Of the 5 χ 10^ cells 
analyzed / sample an average number of 39750 ± 5000 cells (N=10, 5 
samples determined twice) were labeled (stimulation efficiency 79.5 ± 10 
%)· 
Doxorubicin-sensitivity of lymphocytes before and after growth 
stimulation 
The doxorubicin concentration that reduced the number of DNA synthesi­
zing cells to 50 % of the control (IC50) averaged a factor 2.5 lower in case 
of drug exposure of stimulated lymphocytes compared to lymphocytes 
exposed prior to stimulation. Table 1 (upper panel) indicates that despite 
inter-individual differences the enhancement of doxorubicin sensitivity by 
growth stimulation is observed in all cases. The observed differences were 
statistically significant (paired comparisons t-test, p= 0.011). 
A representative example (donor C) of the dose-response curves of 
lymphocytes exposed to doxorubicin before and after growth stimulation is 
shown in figure 3.2a. 
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FIGURE 3.2 
Figure 3.2a. DNA synthesizing 
lymphocytes as measured by IdUrd 
incorporation which have been 
exposed to doxorubicin before ( ) or 
after ( ) stimulation with PHA/IL-2. 
The percentage IdUrd positive (DNA 
synthesizing) cells relative to control 
cells (ordinate) is plotted against 
the doxorubicin exposure 
concentration (abscissa). 
Figure 3.2b. Sensitivity to 
doxorubicin of non-proliferating 
lymphocytes ( ) versus proliferating 
lymphocytes ( ) related to cellular 
doxorubicin concentrations. The 
percentage IdUrd positive (DNA 
synthesizing) cells related to the 
control (ordinate) is plotted against 
cellular doxorubicin concentrations 
(abscissa, arbitrary fluorescence 
units) as determined by flow cytome­
try. 
Cellular doxorubicin concentrations in lymphocytes in relation to the 
proliferative state and doxorubicin sensitivity 
In figure 3.2b cellular doxorubicin concentrations (of the same experiment 
as presented in 2a) are plotted against the number of IdUrd incorporating 
cells. It appears that at the same cellular drug concentrations, the toxicity in 
previously non-stimulated cells is lower than in the cells which had been 
stimulated prior to drug exposure. 
Doxorubicin-sensitivity of CFU-GM before and after growth stimula­
tion 
In unexposed control samples an average of 147 ± 44 colonies and 36 ± 8 
clusters (N=10, 5 samples before and 5 samples after stimulation) were 
as 
ο ι о 2 о 3 о * o s o e 0.7 о.а с β i o ι ι 
extracellular doxorubicin (ид/ml) 
200 400 EOO 
intracellular doioruDicin 
(arbitrary unitaceli) 
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formed (average plating efficiency 0.09%). 
The number of colonies after drug exposure were compared with that of the 
unexposed control cells which was defined as 100 %. The doxorubicin 
concentration reducing colony formation to 50% of the control (IC50) 
averaged a factor 3.4 lower when CFU-GM were stimulated prior to 
doxorubicin exposure. The ratio between colonies and clusters was not 
influenced by doxorubicin exposure (data not shown). 
Table 1 (lower panel) shows the IC50 concentrations as determined for bone 
marrow of five different donors. In analogy with the lymphocyte data, it is 
shown that despite inter-individual differences in doxorubicin sensitivity of 
CFU-GM, the enhancement of drug sensitivity by growth stimulation is 
observed in all cases. The differences were statistically significant (paired 
comparisons t-test, p= 0.003) 
Table I. 
Doxorubicin IC50 concentrations for lymphocytes (upper panel) and bone marrow 
granulocyte/monocyte colony forming cells (lower panel) exposed to the drug before or after 
growth stimulation. 
Lymphocyte 
Donor 
A 
В 
С 
D 
E 
IC50 non-stimulated 
(NS) Mg/ml 
08 
1 4 
10 
04 
1.1 
IC50 stimulated (S) 
Mg/ml 
03 
04 
04 
0.2 
0.5 
ratio NS/S 
2 7 
29 
25 
2.0 
22 
Bone Marrow 
Donor 
A 
В 
С 
D 
E 
IC50 non-stimulated 
(NS) μ&ΛηΙ 
06 
03 
03 
05 
06 
IC50 stimulated (S) 
Mg/ml 
0.2 
0.1 
0 1 
01 
02 
ratio NS/S 
3 
3 
3 
5 
3 
Figure 3.3 shows a representative example (donor D) of a dose-response 
relation of CFU-GM cells exposed to doxorubicin before or after growth 
stimulation. 
63 
Chapter 3: Cell Proliferation and Doxorubicin Toxicity 
FIGURE 3.3 
Sensitivity of human clonogenic bone 
marrow cells (CFU-GM) exposed to 
doxorubicin before ( ) or after ( ) 
stimulation with HPCM. The number 
of colonies (ordinate), expressed as 
percentage relative to control cells is 
plotted against doxorubicin exposure 
concentration (abscissa). 
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DISCUSSION 
Doxorubicin is an anti-cancer drug that exerts cytotoxicity towards all cells 
with proliferative potential, although it has been found that the toxicity is 
less pronounced in quiescent cells compared to proliferating cells [10,11]. 
Most studies concerning doxorubicin sensitivity in relation to cell 
proliferation have been performed on cell lines, where cells were induced 
artificially to a non-proliferative state by growth inhibition as a result of 
suboptimal culturing conditions. In order to study the proliferation-
dependent toxicity in normal human hematopoietic cells, we have used 
lymphocytes and bone marrow cells stimulated before or after drug 
exposure. As a parameter for drug toxicity the inhibitory effects on DNA 
synthesis (lymphocytes) and the colony formation (CFU-GM) have been 
measured. The experimental conditions for the unstimulated and stimulated 
cells were made identical in order to arrive at results where differences in 
drug sensitivity could be due only to variations in the proliferation activity. 
With both peripheral blood lymphocytes as well as with CFU-GM an 
enhancement of the doxorubicin toxicity was observed when the cells had 
been stimulated to growth prior to, rather than after the exposure to 
doxorubicin. In general, stimulation before drug exposure reduced the 
median IC50 concentration from 0.55 μg/ml to 0.20 μg/ml. The in vivo 
plasma levels of doxorubicin, which are attained during a 2 hrs infusion of 
40 mg/m2, have been calculated to arrive at 0.4 μg/ml [17,18]. These 
concentrations are in the range of the in vitro IC50 concentrations observed 
in this study, which implies that with this treatment scheme a considerable 
number of quiescent cells may escape from doxorubicin toxicity. At present, 
this escape phenomenon can not be circumvented by increasing the 
administered drug dose because of intolerable cardiotoxicity [19,20]. 
Cellular doxorubicin concentrations have been described to correlate well 
with toxicity [21,22]. The lymphocyte data demonstrate however that 
differences in doxorubicin toxicity still exist between proliferating and non-
proliferating lymphocytes at comparable cellular doxorubicin 
concentrations. This observation is supported by reports of others [11,23,24] 
who were unable to correlate cellular doxorubicin concentrations with 
proliferation-related differences in doxorubicin toxicity. Impaired drug 
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uptake or drug extrusion are apparently not the primary cause of relative 
doxorubicin resistance in (intrinsically) non-proliferating cells. Cellular drug 
concentrations of CFU-GM were not measured since this would be 
considerably biased by the vast majority ( > 99.9% ) of non-clonogenic cells. 
Environmental conditions that influence the proliferative state of cells by 
creating suboptimal growth conditions (nutritional and oxygen deficits) 
often also effect local drug delivery. If these environmental conditions are 
not taken into consideration as a cause for escape from drug toxicity, 
proliferation-related differences in cellular target availability offer the most 
probable explanation for the observed decreased drug toxicity. Candidates of 
interest in this regard are the topoisomerase enzymes of which the amount 
and activity are known to be closely related to the cell proliferation [24,25] 
and of which topoisomerase II has been identified as an important target for 
doxorubicin [26]. 
In conclusion, non-proliferating normal hematopoietic cells with 
proliferation potential, are relatively less sensitive to doxorubicin toxicity 
compared to their stimulated, proliferating, counterparts. This might explain 
the recovery of hematopoiesis after anti-cancer treatment with doxorubicin 
and also, at least in part, the relapses of malignancies after cytoreductive 
therapy by leaving the malignant quiescent clonogenic cell unharmed. 
Identification of biological response modifiers that are able to preferably 
trigger the quiescent malignant clonogenic cells into cycle could lead to 
enhancement of (differential) doxorubicin toxicity. 
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ABSTRACT 
The effect of growth stimulation on the sensitivity of normal and leukemic 
human bone marrow progenitors to Idarubicin and Doxorubicin was studied 
Clonogenic assays for colony forming units of the granulocyte/macrophage 
lineage (CFU-GM) and leukemic clonogenic cells (CFU-L) were applied 
using human placenta conditioned medium (HPCM) as source of growth 
factors Before seeding cells in clonogenic assay they were exposed to the 
anthracyclines for 2 h without a pre-incubation, or following a 48 h pre­
incubation period in the presence of HPCM. Drug concentrations used 
ranged from 0 001-0.1 μg/ml for Idarubicin and from 0.1-1.5 μg/ml for 
Doxorubicine. In addition, a limited number of bone marrow samples were 
exposed to the cytostatically active metabolite of Idarubicin, Idarubicinol 
(Idol; range 0 001-0 1 μg/ml) Proliferation of CFU-GM and CFU-L during 
48 hours was measured by Iododeoxyuridine (IdUrd)-incorporation. 
Spontaneous proliferation of CFU-GM increased from 38% to 88% after 48 
h stimulation by HPCM. The mean number of proliferating CFU-L increased 
from 40% to 77% when stimulated with HPCM. Doxorubicin inhibited 
colony formation of CFU-GM and CFU-L to 50% (IC50CFU-GM, 
IC50CFU-L) at mean concentrations of 0.355 μg/ml and 0 103 μg/ml when 
applied before pre-incubation with HPCM and 0.108 μg/ml and 0 055 μg/ml 
when applied after pre-mcubation. Idarubicin appeared the most potent drug 
in all experiments regardless the pre-mcubation procedure or sample origin, 
with average IC50CFU-GM and IC50CFU-L of 0 008 μg/ml and 0 006 μ 
g/ml, respectively, when applied before pre-incubation with HPCM and 
0 006 μg/ml and 0 005 μg/ml when applied after pre-incubation with 
HPCM. Idarubicinol showed intermediate potency with average IC50CFU-
GM of 0 022 μ^ττύ and 0 023 μg/ml when applied before and after pre­
incubation with HPCM, respectively. In order to assess the effect of growth 
stimulation on drug sensitivity, samples were evaluated pair-wise 
(sensitivity of the same sample before versus after pre-incubation with 
HPCM) and were submitted to the Wilcoxon test for matched pairs 
Statistically significant enhancement of cytotoxicity was demonstrated for 
Doxorubicin versus CFU-GM (p < 0 021) and a strong trend versus CFU-L 
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(p = 0.06). The data further demonstrate that proliferation-dependency of 
Doxorubicin toxicity is more pronounced for CFU-GM than for CFU-L. 
These data also show that Idarubicin and Idarubicinol toxicity is 
proliferation-independent. Idarubicin is relatively more potent than 
Doxorubicin in suppressing the growth potential of low- or non-proliferating 
progenitors. The in vitro IC50 of Idarubicin appeared a factor 10 lower than 
the in vivo reached plasma levels achieved after standard dose bolus 
injections of Idarubicin. In addition, the data show that Doxorubicin exerts a 
higher differential toxicity towards leukemic progenitors compared to 
Idarubicin and Idarubicinol. 
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INTRODUCTION 
The anthracyclines Doxorubicin (Dox) and Daunorubicin (Dnr) are 
among the most effective drugs in the treatment of leukemia. Idarubicin 
(Ida) is a Dnr derivate which is currently subject of several clinical trials 
motivated by its well established improved in vitro toxicity [1,2], antitumor 
and antileukemic activity [3,4] and reduced cardiotoxicity [5] compared to 
Doxorubicin and Daunorubicin. 
Primary and acquired drug resistance in acute myelogenous leukemia 
(AML) is a fundamental problem in the treatment of AML. One type of drug 
resistance is the result of the relative insensitivity of (malignant) quiescent 
cells to the toxic effects of chemotherapy, which is referred to as 'kinetic 
resistance'. An approach to overcome kinetic resistance is to administer 
chemotherapy together with growth stimulatory factors in order to trigger 
the quiescent cells into an enhanced proliferative state rendering them more 
sensitive to drug toxicity. Using this approach in vitro, increased sensitivity 
of normal [6] and leukemic [7] human hematopoietic cells to Doxorubicin 
has been reported. The present study evaluated whether the previously 
described proliferation-dependency of Doxorubicin toxicity also applied to 
Idarubicin or its 13-hydroxy derivative, Idarubicinol (Idol). 
The effect of short-term drug exposure of normal myeloid human bone 
marrow progenitors (colony forming units of the granulocyte/macrophage 
lineage; CFU-GM) and leukemic progenitors (CFU-L) during normal state 
and after growth stimulation was compared. Drug concentrations were 
chosen to be within the range of clinically achievable plasma cells. In vivo, 
plasma levels of Doxorubicin attained after a 2 h infusion of 40 mg/m^ are 
about 0.4 μg/ml [8,9], while peak plasma levels of Idarubicin after a bolus 
injection of 10 mg/m^ reach 0.05 ± 0.02 μg/ml [10]. In vivo, Idarubicin is 
rapidly metabolized to Idarubicinol resulting in Idarubicinol plasma levels 
which exceed Idarubicin levels 2-4 h after administration [11]. The 
cytostatic activity of Idarubicinol has been reported to be comparable to its 
parent compound [12,13]. 
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MATERIALS AND METHODS 
Bone marrow sampling, isolation of nucleated cells and 
cryopreservation. 
Normal sternal bone marrow aspirates were obtained from cardiac surgery 
patients. Leukemic bone marrow samples were obtained from previously 
untreated patients presenting with acute myelogenous leukemia. Informed 
consent was given in all cases. The aspirates were collected in sterile 
buffered acid citrate dextrose (pH 7.0). 
Contamination of the aspirates with nucleated peripheral blood cells was 
calculated as described previously [14]. Only aspirates with less than 20% 
peripheral blood admixture were used for this study. The bulk of red cells 
and polynuclear cells were removed by density gradient centrifugation with 
Ficoll (density 1.085 g/ml, Sigma, St. Louis, MI). Leukemic bone marrow 
samples were cryopreserved as described previously [15]. In short: One 
milliliter vials containing 5-20 χ 10" cells in Iscove's medium (Flow 
Laboratories, Irvin, Scotland) supplemented with 5% (v/v) fetal calf serum 
(FCS; HyClone, Logan, UT) and 10% (v/v) dimethylsulfoxide, were frozen 
in liquid nitrogen using a temperature-controlled freezer (Kryo 10; Planer 
Biomed, Middlesex, UK). Just prior to the experiments, the cells were 
thawed rapidly in a 37°C waterbath, resulting in a cell recovery of >90%. 
Following separation (normal bone marrow aspirates) or thawing (leukemic 
bone marrow samples), cells were washed twice with phosphate buffered 
saline (PBS) to which 1% fetal calf serum (FCS) was added and were 
resuspended in Iscoves medium + 20% FCS. 
Drug exposure and cell culture 
Prior to drug exposure, cell suspensions were incubated in a shaking 
waterbath (37°C, 0.5 h). Doxorubicin, Idarubicin (Farmitalia Carlo Erba, 
Milan, Italy), or Idarubicinol (gift from Dr. Ganzina, Farmitalia Carlo Erba, 
Milan, Italy) from a frozen stock prepared in PBS to arrive at final drug 
concentrations as described under results were added to the cell suspensions 
(105 cells/ml). Incubations were stopped by washing the cells three times 
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with PBS+ 1% FCS. 
One part of each sample was exposed to the drugs for 2 h after which they 
were washed three times and plated in duplicate in clonogenic assays. The 
other part of samples were first incubated for 48 hours (105 cells/ml, 5% 
CO2 in a fully humidified atmosphere) in Iscove's medium supplemented 
with 20% FCS and 5% (v/v) Human Placenta Conditioned Medium (HPCM) 
[16]. Since the cells were incubated at a low concentration of 10^ cells/ml, 
the number of CFU-GM and CFU-L remained constant or increased slightly 
during the 48 hours incubation period independent of the presence of HPCM 
as described before [17]. After 48 hours these samples were exposed to the 
drug for 2 hours and handled as described for the other samples. The IC50 of 
clonogenic cells after exposure to anthracycline for 2 h was not influenced 
by a pre-incubation for 1 or 48 hours in medium without HPCM. In one 
particular experiment the IC50 of CFU-L was 0.207 μg/ml when 
immediately plated after exposure to Doxorubicin and the IC50 was 0.248 μ 
g/ml when the cells were exposed to Doxorubicin after a pre-incubation 
period of 48 hours. 
CFU-GM and CFU-L clonogenic assays 
In vitro growth conditions for CFU-GM and CFU-L are identical [17]. 
Clonogenic assays were performed in duplicate in 35 mm Petri dishes 
(Costar, Cambridge, Mass, USA) as described previously [18]. In brief: each 
dish contained 2 ml of a cell suspension in Iscove's medium (Flow 
Laboratories, Irvine, Scotland) supplemented with 20% (v/v) FCS, 5% (v/v) 
HPCM and 0.3% (w/v) bacto agar (Difco, Detroit, MI, USA). Cells were 
plated at previously determined cell densities in order to arrive at an 
adequate number of 100-200 aggregates/dish. The cultures were incubated 
at 37°C in a fully humidified atmosphere of 5% CC»2 in air. After 14 days 
the number of clusters (> 5 cells, < 50 cells) and colonies (> 50 cells) were 
scored. The number of aggregates (colonies + clusters) in drug treated 
cultures were evaluated relative to that in control cultures and dose-response 
curves were constructed. Curve fitting was performed as described previous­
ly [17] and drug concentrations resulting in 50% inhibition of clonogenicity 
(IC50) were calculated from these curves. 
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Assessment of proliferative activity of CFU-GM and CFU-L 
In order to evaluate the effect of HPCM on the proliferative activity of CFU-
GM and CFU-L their ability to incorporate Iododeoxyuridine (IdUrd) was 
determined. IdUrd is a thymidine analogue which is incorporated into DNA 
during S-phase. Incorporated IdUrd can be detected by anti-IdUrd antibodies 
[19,20]. We have developed a method to assess proliferating progenitor cells 
by labeling with IdUrd followed by immunoperoxidase staining to detect 
incorporated IdUrd in myeloid colonies. Technical details and validation of 
the method will be published in a separate manuscript. 
IdUrd incorporation in CFU-GM and CFU-L 
In short, normal bone marrow cells (10^ cells/ml) were resuspended in 
Iscove's medium supplemented with 20% FCS, 50 IU/ml penicillin, and 50 μ 
g/ml streptomycin. Cell suspensions were divided into two subcultures 
which were either non-stimulated or stimulated by the addition of 5% (v/v) 
HPCM. To both the nonstimulated cultures and stimulated cultures, IdUrd 
was added from a frozen stock prepared in PBS, to arrive at a final 
concentration of 1 μΜ. The concentration of 1 μΜ was chosen since this 
was the highest concentration of IdUrd which was not cytotoxic for CFU-
GM during continuous exposure (data not shown). Cells were incubated in 
suspension in the presence of IdUrd for 2 days at 37°C, in a fully humidified 
atmosphere of 5% C02 in air. 
Following incubation cells were washed three times with glucose-phosphate 
buffered saline and plated for clonogenic assay in IdUrd-free medium as 
described [17] with one minor modification in that the total volume of the 
cell preparations in semi-solid medium plated per dish was reduced to 0.85 
ml. Cultures were incubated for 5-7 days at 37°c, in a fully humidified 
atmosphere of 5% CO2 in air during which cell aggregates had been formed 
of 20-60 cells. 
Since the cells were only exposed to IdUrd before plating in clonogenic 
assay, any detectable incorporated IdUrd in the cell aggregates must have 
been derived from IdUrd which was incorporated initially by the single 
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clonogenic cell from the colony or cluster originated. Thus, detectability of 
IdUrd in the colonies provides information of the proliferative state of the 
clonogenic cell before plating. For each experiment, a sample which was not 
labeled with IdUrd served as a negative control. 
Preparation of agar cultures for immunoperoxidase staining 
After counting the clusters and colonies the agar cultures were dried using a 
modification of the method described by Baines [21]. The agar cultures were 
cut into 2 halves and shaken into glucose phosphate buffered saline. Each 
half was lifted onto a 76 χ 26 mm glass slide and covered with a cellulose 
acetate strip (Sepraphore, Gelman Sciences, Ann Arbor, MI). Next, a piece 
of filter paper (Schleicher & Schuell, Dassel, Germany) was put on top 
followed by a cytospin filter card. The slides were left to dry partially for 30-
60 min at room temperature. Subsequently, the slides were put into cytoclips 
together with the regular plastic cytospin sample chambers and centrifuged 
in a cytospin centrifuge at 1,500 rpm for 10 min. Following removal of the 3 
filter layers a thin layer of agar, in which the colonies and clusters were 
embedded, remained on the glass slide. 
Detection of IdUrd incorporation by indirect immunoperoxidase 
staining 
The method used to detect IdUrd incorporation was adapted from a 
previously published procedure used for flow cytometry [23]. After an initial 
wash step in PBS the slides were treated for 30 min with 1 mg/mi pepsine 
(Serva, Heidelberg, Germany) in 2 N HCL-solution and neutralized by 
addition of 0.1 M Na2B4Û7. Subsequently, an anti-IdUrd monoclonal 
antibody (HN-IU) developed in our laboratory was added. Comparison 
between HN-IU and monoclonal antibody against bromodeoxyuridine which 
cross-reacts with IdUrd (Bu20A, Dakopatts) revealed complete accordance 
(data not shown). Binding of the anti-IdUrd moab was visualized by 
applying a sandwich method of three subsequent additions or peroxidase-
conjugated immunoglobulins (P-Ig), the first being rabbit anti-mouse P-IgG 
(Dakopatts, 1:100 dilution), followed by goat anti-rabbit P-IgG (ICN 
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Biochemicals, Costa Mesa, CA, dilution 1:250) and rabbit anti-goat P-IgG 
(ICN Biochemicals, 1:250 dilution). In between each step the slides were 
washed with PBS. Peroxidase activity was determined by 10 min incubation 
with 0.5 mg/ml 3,3-diaminobenzidin tetrahydrochloride (DAB, Sigma, St 
Louis, MO), 0.015% H2O2 in PBS (pH 7.8). Slides were washed by running 
tap water and counterstained with hematoxylin. 
Scoring of IdUrd positive colonies 
During microscopic examination of slides which were prepared as described 
above, a cell was considered IdUrd positive when the nucleus contained at 
least one brownish-black spot. Aggregates were scored as IdUrd positive 
when the majority of the cells comprising the aggregate were IdUrd positive. 
Per experiment, 100-200 aggregates were analyzed and the relative 
contribution of IdUrd positive aggregates to the total number of aggregates 
was determined. All slides were evaluated by one technician (M. Hellegers), 
who was not informed of the origin of the slides before evaluation. 
Statistics 
The effect of growth stimulation on drug toxicity was assessed by 
submitting corresponding samples (exposed before and after the start of 
growth stimulation) to the Wilcoxon test for matched pairs. 
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RESULTS 
Doxorubicin, Idarubicin, and Idarubicinol cytotoxicity of CFU-GM 
As shown in table 1, inter-sample variation regarding drug sensitivity was 
observed for all three anthracycline moieties. At comparable drug exposure 
concentrations Idarubicin was always more potent than Doxorubicin while 
Idarubicinol showed intermediate potency. When cells were exposed to 
Doxorubicin before growth stimulation the IC50CFU-GM ranged from 
0.184 μg/ml to 0.651 μg/ml. In all seven experiments pre-stimulation of 
CFU-GM with HPCM resulted in an increased sensitivity to Doxorubicin. 
The mean ratio of the IC50CFU-GM of Doxorubicin without and with pre-
stimulation with HPCM was 3.5 ± 1.4 (SD). The mean dose IC50 was 0.355 
ц§/т1 and 0.108 \içjm\ after stimulation with HPCM (p = 0.02). Exposure of 
the cells to Idarubicin before stimulation with HPCM resulted in IC50CFU-
GM ranging from 0.005 μg/ml to 0.014 μg/ml (mean: 0.008 μg/ml). Pre-
stimulation with HPCM increased the sensitivity to Idarubicin in four out of 
seven samples with IC50CFU-GM ranging from 0.003 μg/ml to 0.012 μg/ml 
(mean: 0.006 μg/ml). In most cases the differences were negligable and the 
overall increase in sensitivity was not significantly different (p = 0.21). The 
mean ratio of the IC50CFU-GM of Idarubicin without and with pre-
stimulation with HPCM was 1.9 ± 0.4 (SD). Idarubicinol was less cytotoxic 
when compared to its parent drug. IC50CFU-GM ranged from 0.015 μg/ml 
to 0.034 μg/ml (mean: 0.022 μg/ml) without prior stimulation. Pre­
incubation of the cells with HPCM before drug exposure increased 
sensitivity to Idarubicinol in two out of three cases with IC50CFU-GM 
ranging from 0.012 μg/ml to 0.040 μg/ml (mean: 0.023 μg/ml). This 
difference was not significant. 
In one case sufficient nucleated bone marrow cells were available to 
compare the effect of all three drugs on the same sample. Also when the 
three drugs were tested on samples taken from one donor, the pattern of 
toxicities as described above was confirmed. The dose-response curves of 
the three drugs in this particular experiment are shown in figure 4.1. 
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Figure 4.1. 
Dose-survival relation between Doxorubicin (triangles), Idarubtctn (circles) and Idarubicinol 
(squares) versus CFU-GM exposed before (open figures) or after (closed figures) addition of 
growth f actors (experiment no. 3 of table I). 
Table I 
1С'so concentrations (pg/l) of Doxorubicin, Idarubicin and Idarubicinol versus normal bone 
marrow CFU-GM. Individual samples were exposed for 2 h to the drugs before (-HPCM) or 
after (+HPCM) a 48 h рте-incubation period m the presence of HPCM. 
mean 
Ρ 
á :_ 
Doxorubicin 
-HPCM 
0 297 
0 560 
0 184a 
0 391 
0 197 
0 651 
0 204 
0 355 
0 02 
:„,„_» A 
+HPCM 
0 087 
0114 
0 075a 
0 062 
0 085 
0 253 
0 077 
0 108 
Idarubicin 
-HPCM 
0.005 
0 005 
0 005a 
0 009 
0012 
0 005 
0 014 
0 008 
NS 
+HPCM 
0 006 
0 003 
0 004a 
0010 
0 005 
0 005 
0012 
0 006 
Idarubicinol 
-HPCM 
0 015 
0 034 
0 017a 
0 002 
. J ~ „ «„«. 
NS 
+HPCM 
0 040 
0 016 
0 012a 
0 023 
Complete dose survival curves of this experiment are given in figure 4 1. 
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Doxorubicin, Idarubicin and Idarubicinol cytotoxicity of CFU-L 
The Doxorubicin concentration reducing colony formation of unstimulated 
leukemic colony forming cells (CFU-L) to 50% (IC50) ranged from 0.058 to 
0.216 μg/ml (table II). IC50 of CFU-L following stimulation with HPCM 
ranged from 0.034 - 0.098 μg/ml. The IC50 of Doxorubicin averaged 0.103 
μg/ml without stimulation of CFU-L and 0.055 μg/ml after prior stimulation 
of CFU-L. In all five experiments pre-stimulation of CFU-L with HPCM 
resulted in an enhanced sensitivity to Doxorubicin. The increase of cytotoxi­
city was not significant in part due to the limited number of experiments but 
showed a strong trend (p = 0.06). 
The Idarubicin concentration that reduced the number of unstimulated CFU-
L to 50% ranged from 0.002 to 0.011 μg/ml and from 0.002 to 0.010 μg/ml 
after stimulation with HPCM. Limited enhancement of Idarubicin sensitivity 
after growth stimulation by HPCM was observed in four out of five cases, 
but this difference was weak and not significant (p = 0.21). 
The IC50 of Idarubicinol was not significantly influenced by stimulation 
with HPCM. Idarubicinol was slightly less cytotoxic when compared with 
Idarubicin (table II). 
The IC50 of Doxorubicin was considerably lower than when unstimulated 
CFU-L were exposed to Doxorubicin compared to normal CFU-GM (0.103 
μg/ml versus 0.355 μg/ml). This difference was maintained after stimulation 
with HPCM. The IC50 of Doxorubicin of stimulated CFU-L was 0.055 μ 
g/ml compared to 0.108 μg/ml of stimulated CFU-GM. In contrast IC50 of 
Idarubicin of normal CFU-GM and leukemic CFU-L were in the same range 
(table I and II) independant of stimulation with HPCM. 
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Table II 
IC50 concentrations fag/ml) of Doxorubicin, Idarubicm and Idarvbicinol versus leukemic bone 
marrow CFU-L as determined by clonogenic assay. Individual cell samples were exposed to the 
drugs before (-HPCM) or after (+HPCM) a 48 h incubation period m the presence ofHPCM 
Patient Doxoru 
К 
M 
Ρ 
J 
R 
mean 
Ρ 
-HPCM 
0 072a 
0 085 
0216 
0 058 
0 083 
0 103 
0 06 
ЭІСІП 
+HPCM 
0 034 
0 067 
0 098 
0 039 
0 037 
0 055 
Idarubicin 
-HPCM 
0006 
ООП 
0 002 
0 006 
0 006 
NS 
+HPCM 
0 002 
0010 
0 003 
0 005 
0 005 
Idarubicinol 
-HPCM 
0 009 
ООП 
0010 
NS 
+HPCM 
0 014 
0 010 
0 012 
Leukemic marrow samples were obtained from five patients with untreated AML All 
marrow vials of each patient were obtained from the same aspirate 
Proliferation of CFU-GM and CFU-L 
Proliferation of CFU-GM and CFU-L during 48 hours was measured by 
Iododeoxyundine (IdUrd) incorporation. The period of 48 hours was chosen 
since we assumed that in most samples the total cell cycle would be in this 
range [24]. The data obtained on two normal bone marrows and on all five 
leukemic marrows used in this study are shown in figure 4.2. One normal 
bone marrow was measured immediately after aspiration, the second sample 
was cryopreserved marrow. Thirty-eight percent (mean of two experiments) 
of the CFU-GM were IdUrd positive when incubated without exogenous 
growth factors. This number increased to 88% during 48 hours incubation in 
the presence ofHPCM (figure 4.2). The mean number of proliferating CFU-
L increased from 40 ± 27% to 77 ± 16 when stimulated with HPCM during 
48 hours. Patients Κ, Μ, Ρ and J did not grow in vitro in the absence of 
exogenous growth factors in contrast to patient R. The number of IdUrd 
positive colonies of this patient showed a modest increase from 86% to 
98%. 
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% IdUrd positive colonies 
100 г 
BO 
60 
4 0 
2 0 
Normal Normal 
Marrow Marrow 
without HPCM with HPCM 
Figure 4.2. 
Percentage of colony forming cells (CFU-GM of CFU-L) that have incorporated IdUrd during 
incubation for 48 hours in the presence of ΙμΜ IdUrd with or without HPCM. The samples 
(K/R) correspond with the same sarnies (K/R) of table II. 
86 
Chapter 4: Cell proliferation and Anthracycline Toxicity 
DISCUSSION 
Normal and leukemic hematopoiesis have in common that both are 
maintained by a relatively small population of clonogenic cells. Succesful 
treatment of leukemia should therefore not only be directed at eradication of 
the bulk of malignant cells with limited or no clonogenic capacity but also at 
elimination of leukemic clonogenic cells. The fact that normal blood counts 
can be observed after an initial aplastic phase following anthracycline-based 
remission induction courses demonstrates survival of normal hematopoietic 
clonogenic cells. However, also a majority of AML patients with remission 
after chemotherapy relapse. This indicates that some leukemic clonogenic 
cells also escape cytotoxic treatment. 
An explanation for the in vivo escape of clonogenic cells from 
anthracycline toxicity might be their low proliferative state during drug 
exposure. It was recently demonstrated that growth stimulation increased 
sensitivity of normal [6] and leukemic [7] clonogenic cells to Doxorubicin in 
vitro. This study confirmed the enhanced cytotoxicity of Doxorubicin after 
stimulation of CFU-L by HPCM. At present, a still increasing panel of 
growth stimulatory and growth inhibitory factors becomes available which 
allows specific manipulation of the proliferative activity of hematopoietic 
progenitors. These exciting developments in the field of growth modulation 
justifies further studies to determine whether the moderate differential 
toxicity of Doxorubicin observed in this study can be improved by using a 
combination of more specific growth modulators. Proliferation of clonogenic 
cells was measured by IdUrd-incorporation during 48 hours. Prolonged 
IdUrd labeling provides the unique opportunity to determine the 
proliferating fraction of progenitor cells. With the traditional techniques, 
including tritium-Thyrnidine suicide techniques only the fraction of S-phase 
cells can be determined. 
The IC50 averaged a factor of 3.5 lower when CFU-GM were 
stimulated by HPCM prior to Doxorubicin exposure. The reduced IC50 of 
Doxorubicin was a factor of 1.9 lower when CFU-L were stimulated by 
HPCM. Spontaneous proliferation of normal CFU-GM in absence of 
exogenous growth factor was about 38%. The number of IdUrd positive 
colonies increased to 88% after 48 hours stimulation by HPCM. 
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Proliferation of CFU-L was enhanced in all 5 tested leukemic samples. The 
mean number of proliferating CFU-L increased from 40 to 77% when 
stimulated with HPCM. In one patient (R) the number of IdUrd positive 
colonies increased only marginally after stimulation with HPCM, but 
Doxorubicin cytotoxicity increased similarly compared to the other four 
patients. This may be explained by an enhanced proliferation of already 
proliferating colony forming cells induced by HPCM. But alternative 
explanations can not be ruled out. This means that in vivo administration of 
a recombinant growth factor such as GM-CSF or G-CSF during remission-
induction therapy may enhance CFU-L sensitivity to Doxorubicin. But it 
may also potentially dangerous by prolonging the period of bone marrow 
hypoplasia due to a more enhanced sensitivity of normal CFU-GM. 
Idarubicin and Idarubicinol were able to achieve comparable reduction 
in number of normal and leukemic clonogenic cells as Doxorubicin, but at 
much lower drug concentrations. Peak plasma concentrations observed in 
vivo when 10 mg/ітг Idarubicin is administered as an intravenous bolus 
injection are about 0.05 ng/ml [10]. Thus in vitro IC50 concentrations 
observed for Idarubicin and Idarubicinol are more readily achievable in vivo 
when compared with Doxorubicin. 
The IC50CFU-GM concentrations observed after a 2h drug exposure 
used in the present study are in the same range with previously [13] reported 
IC50 concentrations (0.007 μg/ml and 0.017 μg/ml) for Idarubicin and 
Idarubicinol respectively, [13] when a drug exposure of 30 min was used. 
Drug uptake studies have demonstrated that in human bone marrow cells 
(cell type dependent) steady state levels of Idarubicin are achieved in 0.5 h 
to 3 h [23]. Therefore, considering that the cellular drug concentrations 
achieved within 30 min and 2 h exposure times will not be very different, 
the close range between the IC50 data is conceivable. This demonstrates 
however, that for Idarubicin the extracellular concentration χ time product is 
less informative than the cellular drug concentration as a predictive 
parameter for drug toxicity. 
Growth stimulation did not significantly enhance sensitivity of CFU-
GM or CFU-L to Idarubicin or Idarubicinol. This indicates that for 
Idarubicin/Idarubicinol the proliferative state of clonogenic cells is less 
important than in case of Doxorubicin. Therefore, Idarubicin is expected to 
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be more effective in killing non- or low proliferating cells compared to 
Doxorubicin. It should be noted however that together with the higher 
toxicity of Idarubicin a reduction of differential toxicity between normal and 
leukemic progenitors is observed in contrast to Doxorubicin. 
Many mechanisms may contribute to the escape of cells from 
anthracycline toxicity in vivo. Kinetic resistance of clonogenic cells and 
modulation of their sensitivity (resistance) by growth modulating factors 
was the subject of this study. MDR-1 overexpression has been demonstrated 
in many hematological malignancies [25-32]. The MDR-1 overexpression 
may also contribute to anthracycline resistance. A vinblastine-resistant 
human lymphoblastic leukemia cell-line CEM-VBL demonstrated minimal 
Daunorubicin uptake. Simultaneous incubation with the MDR modulating 
drug verapamil increased cellular DNR uptake 4-fold. In contrast, Idarubicin 
uptake was 10-times higher compared to DNR. Simultaneous incubation 
with Idarubicin and verapamil resulted in only a 1.2-fold increase of 
intracellular Idarubicin [33]. DNR alone had minimal effect on the 
clonogenic growth of CEM-VBL cells whereas the combination of DNR and 
verapamil resulted in 80% growth inhibition. Incubation of these cells with 
Idarubicin alone resulted in > 95% inhibition [33]. These data have to be 
confirmed in CFU-GM and CFU-L, but they suggest that Idarubicin may be 
more effective than DNR (and Doxorubicin) in leukemia cells that display 
the MDR phenotype. Recent data indicate a close correlation of CD34 
antigen and MDR expression on the surface of clonogenic cells which may 
explain the better activity of Idarubicin against nonproliferating clonogenic 
cells [34]. 
In conclusion, the present study demonstrates that enhancement of 
sensitivity to Doxorubicin by growth stimulation is more pronounced for 
normal CFU-GM than for clonogenic cells from patients presenting with 
acute myeloid leukemia. In addition, it is demonstrated that using identical 
experimental settings, growth stimulation did not effect the sensitivity of 
these progenitors to Idarubicin or Idarubicinol. 
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ABSTRACT 
Cell kinetics of two human leukemic cell lines (Molt-4, K562) following a 2 
h exposure to doxorubicin were studied. 
DNA flow cytometry provided static information that for both cell lines a 
dose-dependent accumulation occured at the G2+M compartment which 
disappeared in time. 
Kinetic information was provided by time-monitoring cells labeled with 5-
iodo-2-deoxyuridine (IdUrd) by two parameter flow cytometry, analyzing 
the IdUrd label and the DNA content. The cell cycle time (Tc) of 
exponentially growing Molt-4 cells was determined to be 20 h. Twenty-four 
hours after a 2 h exposure to 0.25 pg/ml doxorubicin, the Tc had increased 
to 23 h and after exposure to 1.0 μg/ml to 33 h. 
Cell kinetics of K562 cells following doxorubicin exposure were monitored 
in time up to 4 days. The average Tc of exponentially growing K562 cells 
was determined to be 24.7 h. Twenty-four hours following 2 h exposure to 
0.25 or 0.5 μg/ml doxorubicin the Tc's were determined to be 28 and 32 h, 
respectively. After an additional two days the Tc's were determined to be 
both 24 h. The dose-dependent, reversible cell cycle delay which persisted at 
least 48 h should be taken into account as an additional mode for decrease of 
a (tumor) cell population doubling time after exposure to doxorubicin. 
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INTRODUCTION 
Doxorubicin is a powerful, non-cell cycle specific [1], cytostatic drug which 
is included in many anti-cancer treatment regimens. Because of the frequent 
combination with cell cycle specific drugs (e.g. the antimetabolite Ara-C) it 
is essential to have knowledge concerning the effects of doxorubicin on cell 
kinetics. 
The effects of doxorubicin on cell kinetics described are: a) growth 
stimulation after exposure to low dosages [2]; b) cell cycle arrest at the 
G2+M phase after exposure to intermediate dosages [1]; and c) immediate 
cell kill after exposure to high dosages [1]. 
A fourth effect which is of particular importance considering the influence 
on the efficacy of cell cycle specific drugs in combination therapy is d) delay 
of the cell cycle traverse at intermediate dosages. A short-term delay (2-4 h) 
of the cell cycle traverse has been described [1]. However, for these studies 
cell synchronization methods were used which interfere with cell kinetics. 
Moreover, synchronization methods only allow short-term studies on cell 
kinetics due to rapid loss of synchronicity. The 5-iodo-2-deoxyuridine 
(IdUrd) labeling technique provides a tool for direct measurement of cell 
cycle times (Tc) without interference with cell kinetics [3,4] and allowing 
cell kinetic studies over a longer period of time. Therefore, we studied the 
doxorubicin-induced changes in cell kinetics with the IdUrd labeling 
technique, monitoring the cells up to 4 days after the drug exposure. 
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MATERIALS AND METHODS 
Cell lines and culture conditions 
The Molt-4 and K562 human leukemia cell lines were maintained at 
exponential growth in RPMI 1640 medium (Flow Laboratories, Irvine, 
Scotland) supplemented with 10 % (v/v) heat inactivated (HI; 30 min, 56 
°C) fetal calf serum (FCS) (Gibco, Grand Island, NY, USA), 100 μg/ml 
Streptomycin, 100 IU/ml Penicillin and 2 mM L-glutamine (Flow 
laboratories, Irvine, Scotland), which will be referred to as 'Growth 
Medium'. Cells were cultured in a 5% C02-95% air, fully humidified 
atmosphere at 37°C. Cell cultures were routinely checked for absence of 
Mycoplasma infection. 
Drug exposure 
Doxorubicin (Roger Bellon, Neuilly sur Seine, France) was added to a 
final concentration of 0, 0.25, 0.5, and 1.0 μg/ml from a frozen stock made 
in phosphate buffered saline (PBS). Drug incubations were performed at cell 
density of 10^ cells/ml for 2 h in a shaking waterbath at 37 °C. Subse­
quently, the cells were washed twice with glucose phosphate buffered saline 
(GP buffer, 134 mM NaCl, 5.4 mM KCl, 1.4 mM Na2HP04, 3.3 mM 
KH2P04, 5.1 mM glucose) + 1% Ш FCS at 37 °C and resuspended in 250 
ml drug-free Growth Medium at a cell density of 0.01 χ 10" cells/ml and 
returned to the incubator in 150 cm^ flasks (Costar, Cambridge, MA, USA). 
IdUrd labeling and cell sampling 
Prior to the IdUrd labeling (Sigma, St. Louis, MD, USA), cell density were 
adjusted to 1 χ 10° cells/ml. The surplus of medium was saved for 
resuspending the cells after the IdUrd labeling in order to maintain cell 
densities and growth medium conditions close to the conditions prior to the 
labeling. IdUrd was added from a 1.0 M frozen stock in PBS to a final 
concentration of 10 μΜ. After a 30 min incubation at 37°C, cells were 
washed twice with GP buffer and resuspended in the surplus medium that 
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was saved. Subsequently, the 250 ml cell suspensions were each divided in 
series of 25 parallel cultures of 10 ml in 25 cnrr flasks (Costar, Cambridge, 
MA, USA) and were returned to the incubator. At regular time intervals (2-
3 h), one 25 стяг flask from each IdUrd labeling series was taken from the 
incubator, the cells were washed twice in cold (4 °C) PBS + EDTA (0.5 
mM), fixed in cold (-20 °C) 75% (v/v) ethanol/PBS and stored at -20 °C 
until further use. 
Three parallel cultures of K562 cells were labeled with IdUrd on either 0 h, 
24 h, or 70 h post-Dox exposure (T-post). This strategy allowed monitoring 
of cell kinetics for 4 days. 
Molt-4 cells were monitored by one IdUrd labeling on T-post=24 h. 
Estimation of drug toxicity 
Cell densities of one designated flask for each series were determined daily 
by counting samples with a Coulter Counter ZF (Coulter Electronics Ltd, 
Luton, UK). Drug toxicities were estimated by comparing growth curves of 
drug treated cells with those of the control cells. Ultimately, the contribution 
of the killed cells to the size of the total population will be so small that a 
backward extrapolation should give an estimate of the fraction killed. The 
first order regression line for the control cells during logarithmic growth was 
determined. This regression line was used for backward extrapolation of the 
drug-treated data starting from the highest cell density available for each 
curve which was within the range of logarithmic growth (minimizing the 
contribution of dead cells). 
IdUrd/PI flow cytometry 
The stored samples were handled according to the method described by Van 
Εφ et al. [5]. In short: ethanol-fixed cells were washed with PBS, DNA 
denaturated by 30 min incubation with 1 ml pepsin/HCL (1 mg/ml pepsin 
(Serva, Heidelberg, FGR), 2 N HCL) at room temperature followed by 
neutralization with 1 ml 0.1 M sodiumtetraborate. Subsequently, the cells 
were washed twice with PBS, labeled with 20 μ1/10" cells fluorescein 
isothiocyanate (FITC) conjugated anti-BrdUrd monoclonal antibody (Becton 
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Dickinson, NJ, USA) which is cross-reactive with IdUrd. DNA was stained 
with 0.5 ml 25 ng/ml propidium iodide (PI) (Sigma, St.Louis, MI, USA). 
Cells stained with anti-BrdUrd/FITC and PI were analyzed with a flow 
cytometer 50H (Ortho Instruments, Westwood, CA, USA). The 488-nm line 
of a 5-Watt Argon ion laser was used for excitation. A 580-nm di-chroic 
mirror, a high-pass filter RG630 nm (Tor red), and a bandpass filter 515/530 
nm (for green) were used. Five χ 10^ cells were measured at a flow rate of 
approximately 100 cells per second. The area of the green fluorescence 
signal and both area and peak value of the red fluorescence signal were 
recorded in list mode. The ratio area:peak discriminates between artifacts 
due to doublets of diploid cells and real single tetraploid (or late S) cells, 
when intact cells are used. The data were stored on and analyzed with a 
PDP11/34 computer (Digital Equipment, Galway, Ireland). 
Tf analysis 
Cell cycle times were determined according to the method described by 
Pallavicini et al. [6] with modifications. In short: of each sample, green 
fluorescence (IdUrd incorporation) was plotted against red fluorescence 
(DNA content). IdUrd-labeled cells were discriminated from non-labeled 
cells by setting a threshold for background green fluorescence at the level of 
non-IdUrd labeled control cells. The fraction of IdUrd-labeled cells with 
mid-S-phase (lower limit 1.4 χ Gl, upper limit 1.6 χ Gl) DNA content 
(Fraction Labeled S-phase, FLS) at several time intervals after IdUrd 
labeling were analyzed from the sequential IdUrd/DNA distributions. 
The FLS value of the first sample immediately following the IdUrd labeling 
is high (= first maximum), the FLS values decline when the labeled cells 
reach the G2+M and Gl compartment and rise to a second maximum when 
the labeled cells re-enter the S-phase for a second time. From these 
oscillations of the FLS in time the Tc is calculated. The cell cycle time 
corresponds with the time it takes FLS to reach the second maximum. 
Figure 5.1 shows the transition of exponentially growing, IdUrd-labeled 
Molt-4 cells (control cells not exposed to doxorubicin) through the cell cycle 
phases. 
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signal of control (non-IdUrd-labeled) cells. 
curve fitting 
Determination of Tc requires accurate determination of the position of two 
subsequent peaks or nadirs in time. The position of each peak or nadir was 
determined by plotting a 2nd order regression line through the data points 
comprising the curves. 
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PI DNA flow cytometry 
DNA distribution histograms were obtained simultaneously with the 
bivariate IdUrd/PI measurements as described in the previous section. 
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RESULTS 
Drug toxicity 
Growth curves of Molt-4 cells and K562 cells are presented in figure 5.2. 
The first order regression line for the control cells during logarithmic growth 
(solid lines) were used for backward extrapolation of the drug exposed 
curves (dashed lines) to estimate the cell kill. A dose-dependent cell kill 
was observed with both cell lines. The surviving fractions, as determined 
from the growth curves are presented in table I. 
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FIGURE 5.2. 
Growth curves from control О and drug-exposed · , 0.25 pg/ml; D, 0.5 μζ/π>1; V, 1.0 /jg/ml 
Molt-4 cells (left panel) and K562 cells (right panel). The solid lines represent the first order 
regression line for control cells during logarithmic growth. The dotted lines are extrapolations 
of these lines to the drug exposed data. The intercepts of the dotted line with the ordinate give an 
estimate of the initial number of viable cells. 
Dox.conc. 
control 
0.25 
0.5 
1.0 
survival 
Molt cells 
100% 
2 8 % 
ND+ 
0.4 % 
survival 
K562 cells 
100% 
49% 
22% 
ND 
Table I. Drug toxicity of 2 h 
doxorubicin exposure to 
Molt-4 cells or K562 cells as 
estimated from comparing 
growth curves of control cells 
with drug-treated cells. 
(ND= Not Done) 
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DNA flow cytometry 
Cell cycle phase distributions from samples taken before and at several time 
intervals after doxorubicin exposure were monitored. A reversible 
doxorubicin concentration-dependent accumulation at the G2+M phase was 
observed for both cell lines and with all drug concentrations (data not 
shown). An example showing initial accumulation at the G2+M phase and 
subsequent reversal is shown in figure 5.3. 
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FIGURE 5.3. 
DNA histograms ofK562 cells as determined with PI-FCMfollowing 2 h exposure to 0 25 pg/ml 
doxorubicin. Samples were taken at several time intervals post-doxorubian exposure, as 
indicated under each histogram. A drug-induced accumulation of the cells at the G2+M phase is 
observed (T-post=16 h and T-post=30 h). A restoration towards the original distribution is 
observed at T-post= 58 h. 
Tp analysis by bivariate IdUrd/PI flow cytometry 
FLS χ 100 % were plotted against T-post. Figures 5.4 and 5.5 show the 
changes of FLS in time of Molt-4 cells and K562 cells, respectively. Tc were 
determined by measuring the elapsed time between two subsequent peaks 
from the oscillations of the FLS in time. The Tc as determined for each cell 
line are summarized in table II. 
The range of error for determining Tc can be derived from comparing the Tc 
values for K562 control cells as determined on 3 different days. The average 
Tc ± SE for K562 control cells was 24.7 ± 1.4 h. 
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The fractions of doxorubicin exposed K562 cells labeled on T=0 which were 
able to enter a second S-phase following the IdUrd labeling were too small 
to ensure accurate Tc analysis. However, the times elapsed before their FLS 
values reached their nadirs were already prolonged. Control K562 cells 
reached a first nadir at 14 h compared to 18 h and 28 h for K562 exposed to 
0.25 and 0.5 μg/ml doxorubicin respectively. 
For both cell lines, with the T=24 h labeling, a concentration-dependent 
delay of the cell cycle traverse was observed. The K562 data show that the 
cell cycle delay is reversible since the Tc determined with the T=70 h were 
comparable to the control. 
In addition to the cell cycle delay, also a dose-dependent decrease of the 
initial FLS values was observed when comparing drug exposed cells to the 
controls. This might indicate immediate arrest of cells at S-phase (cells with 
S-phase DNA content but no DNA synthesis and therefore no IdUrd 
labeling). If no arrest had occurred (as with the control), approximately all S-
phase cells would have been labeled with IdUrd (initial FLS «1.0). 
Table II. 
Cell cycle times determined'for Molt-4 andKS62 cells following 2h exposure to doxorubicin. 
cell line 
drug exposure 
Molt-4 control 
Molt-4 0 25 \içjm\ 
Molt-4 1 0 μ§/ητ1 
K562 control 
K562 0 25 Mg/ml 
K562 0 5 μ%/π\\ 
Tc day 0 
ND 
ND 
ND 
27 
NE 
NE 
Tc dayl 
20 
23 
33 
22 
28 
32 
Tc day3 
ND 
ND 
ND 
25 
24 
24 
ND= not done 
** 
NE= not évaluable 
The synchronicity of the 3 K562 control cell data (figure 5.5a) is 
coincidental. It is caused by the coincidence of completion of the cell cycle 
traverse of cells labeled by one labeling and the initiation of the next IdUrd 
labeling. 
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72 
Changes ofFLSx 100 % ofMolt-4 cells 24 h following 2 h exposure to0( О О ) , 0.25 (Ύ-
—Ύ) or 1.0 ( D- '- '-D ) μg/ml doxorubicin. Twenty four hours post-drug exposure, the cells 
were labeled with IdUrd (0.5 h, 10 μΚί) and the transition of the IdUrd labeled cells through the 
cell cycle phases was time monitored The fraction of IdUrd-labeled mid-S-phase cells χ 100 % 
(ordinate) is plotted against the time post-drug incubation (abscissa). The lines represent 2nd 
order regression lines determined from the data comprising the corresponding parts of the 
curves. 
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FIGURE 5.5. 
Changes of FLS χ 100 % of K562 
cells following 2 h exposure to 0 (a), 
0.25 (b) or 0.5 (c) μ^Ι 
doxorubicin. The cells were labeled 
with IdUrd (0.5 h, 10 μΜ) either on 
day 0 (T-post= Oh, ) , day 1 (T-
post=24 h), or day 3 (T-post=70 h,). 
The relative number of IdUrd 
labeled mid-S-phase cells (ordinate) 
is plotted against the time post-Dox 
incubation (abscissa). The ¡mes 
represent 2nd order regression lines 
determined from the data comprising 
the corresponding parts of the 
curves. 
Time posl-doxorubicin exposure (hours) 
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DISCUSSION 
In this study, it was demonstrated that doxorubicin not only induces a dose-
dependent cell kill and/or arrest at the G2+M phase but also a dose-depen-
dent long-term delay of the cell cycle traverse. The observed cell kill and/or 
cell cycle arrest are well-established features of doxorubicin toxicity [1]. 
Doxorubicin related delay of the cell cycle has been suggested [7,8] and also 
demonstrated [1]. However, the reported cell cycle delays were only short-
lived (2-4 h) and considering the presently available methods the suitability 
of the methods used can be questioned. 
A frequently applied method to study cell kinetics is monitoring the 
DNA histograms which reflect the static cell cycle phase distribution of an 
overall cell population. However, based on DNA histograms only, a non-cell 
cycle phase specific delay of the cell cycle traverse can not be determined. 
The IdUrd technique used in this study, provides kinetic information and 
therefore provides additional information. 
From the K562 cells labeled on T=0 h it is clear that doxorubicin 
effects the cell cycle traverse almost immediately since the traverse of the 
labeled cells out of the S-phase compartment is already prolonged. This is in 
agreement with previous reports [1]. The increase of FLS at T=0 h following 
the nadir indicates that there are labeled cells re-entering S-phase. We were 
not able to extend the data analysis of T=0 labeled cells beyond the last data 
point presented in each curve due to inaccuracy of the measurements for 
DNA content because of cell death. Therefore it is not known whether these 
cells were destined to die. However, from FLS monitored for cells labeled on 
T=24 h we can state that these labeled cells were able to complete their cell 
cycle (S -> G2+M / Gl = first nadir) and the subsequent cell cycle (Gl -> S 
= second peak; S -> G2+M = second decline of FLS) and therefore had 
survived at least 48 h following drug exposure. It seems unlikely that these 
slow-growing labeled cells were destined to die. 
Data have been published which could be explained by cell cycle 
delay effects of doxorubicin but which were not interpreted as such by the 
authors. In a study by Ellwart et al. [9], survival curves of doxorubicin-
treated HL-60 cells were presented. The curves were constructed exclusively 
based on vital cells by discrimination with fluorescein diacetate. 
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Nevertheless, doxorubicin dose-related dinerences were observed in the 
slopes of the survival curves which were interpreted as delayed drug effects. 
Sasaki et al.[10] observed doxorubicin-induced postponement of the cell 
cycle traverse of HeLa cells while cell cycle progression was not completely 
blocked and bromodeoxyuridine incorporation into DNA was less than one 
third that of the untreated cells. This phenotype fits with a drug-induced 
delayy of the cell cycle traverse. Although the cells in the present study were 
only exposed for 2 h to doxorubicin the cell cycle delay persisted for at least 
48 h. One might expect that the effects of long-term exposure to doxorubicin 
are even more persistent but additional experiments are needed to confirm 
this. 
The observed cell cycle delay after doxorubicin exposure should be 
taken into consideration with short-term survival assays since multiple 
cellular systems will effect or will be effected by cell cycle kinetics. Ar-
tificially high drug effects may be observed when the decline of the 
parameter studied is considered only to be caused by cell kill. An example 
for this might be found in a paper by Zaffaroni et al. [11] in which 
doxorubicin toxicity, determined with a short-term antimetabolic assay and 
a long-term anti-proliferative assay were compared. The authors described 
an overestimation of the effects of doxorubicin determined with the anti-
metabolic assay relative to the anti-proliferative assay. When doxorubicin is 
used in combination with cell cycle specific drugs, the effects on cell 
kinetics of the doxorubicin exposure alone should be considered in order to 
design a rational time schedule for drug exposure. 
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Chapter 6: Growth kinetics o/clonogenic cells following Anthracyclme exposure 
ABSTRACT 
The effects of doxorubicin, daunorubicin and idarubicin on the growth 
of K562 cells was investigated by monitoring the formation of individual 
colonies in semi-solid culture employing an automated image analysis 
system. Drug effects were evaluated using a short term exposure (2 h) at 
clinically achievable drug plasma concentrations. Following drug exposure, 
heterogeneity in growth patterns was observed which was categorized into 
three distinct types, being 1 ) continuous growth at a decreased growth rate; 
2) limited growth; and 3) no growth. In addition to a concentration-
dependent decrease of the growth fraction a reduction of the growth rate of 
the continuously growing colonies was observed. At equitoxic drug 
concentrations, comparable changes in growth rate were observed for each 
of the three anthracyclines studied. It is demonstrated that the fraction of 
cells which escape drug-induced growth arrest with therapeutically 
achievable drug concentrations, display a significant decrease in growth 
rate. 
4 
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INTRODUCTION 
In the treatment of acute leukemias, doxorubicin (Dox), daunorubicin 
(Dnr) and idarubicin (Ida) have all shown good clinical activity. Dox and 
Dnr produce similar remission induction rates and remission duration (1) 
while Ida is as potent as Dnr at 25 % of the dose (2). 
Results of the in vitro cytotoxicity of Dox and Dnr assessed by 
hemopoietic clonogenic assays have not been consistant with some reports 
demonstrating comparable toxicity for both agents (3,4) while others 
showed Dnr to be more potent than Dox (4,5). However, the higher 
cytotoxicity of Ida over Dnr or Dox is well established (3,6,7). 
Clonogenic assays typically evaluate drug toxicity by determining the 
yield in colony numbers following drug exposure relative to control cultures, 
assuming uniform growth kinetics for all cells under evaluation. However, 
we recently described prolonged cell cycle delay observed in human 
leukemia cell lines following exposure to Dox which was studied with two 
parameter iododeoxyuridine/DNA flow cytometry (8). Prolonged cell cycle 
delay could effect colony counts since not all colonies produced by the 
proliferating cells might achieve the predetermined lower threshold for 
colony size at the time of evaluation of a clonogenic assay. However, it is 
important to recognize that all cell aggregates which show continuous 
growth should be considered proliferative units, regardless of their size and 
growth rate. It is important therefore, to evaluate drug effects on all 
continuously proliferating cells since all of them could potentially maintain 
the cell population. 
In the present study we evaluated whether the previously observed 
Dox-induced cell cycle delay (8) could be confirmed by dynamically 
monitoring the formation of individual colonies employing an automated 
image analysis system (9) and how the effect of Dnr and Ida on cell 
proliferation compared with that of Dox. 
* 
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MATERIALS AND METHODS 
Cell line and culture conditions 
The K562 human leukemia cell line was maintained at exponential 
growth in RPMI 1640 medium (Flow Laboratories, Irvine, Scotland) 
supplemented with 10 % (v/v) heat inactivated (Ш; 30 min, 56 °C) fetal 
bovine serum (FBS) (Gibco, Grand Island, NY, USA), and 2 mM L-
glutamine (Gibco, Grand Island, NY, USA), which will be referred to as 
'Growth Medium'. Cells were cultured in a 5% CC»2-95% air, fully 
humidified atmosphere at 37°C. Cell cultures were routinely checked for 
absence of Mycoplasma infection by screening with a molecular probe for 
prokaryotic ribosomal RNA (Gen-Probe Inc., San Diego, CA). 
Drug exposure 
Dox (Farmitalia Carlo Erba, Milan, Italy), Dnr (Rhone Poulenc, 
France) or Ida (Farmitalia Carlo Erba, Milan, Italy) were added to achieve 
the desired final drug concentrations from frozen stocks prepared in 
phosphate buffered saline (PBS). Drug incubations were performed at cell 
densities of 1 χ 10^ cells/ml for 2 h in a shaking waterbath at 37 °C. Cells 
were washed twice with PBS + 1% Ш FBS and resuspended in drug-free 
Growth Medium. 
Colony formation assay and image analysis 
The colony formation assay and image analysis was performed as 
described previously (9) with minor modifications with regard to the cell 
plating procedure. In short, cells were plated in duplicate in a three layer 
agar sandwich system in 6-well plates (35 mm well diameter; Falcon 
#3046). A 100 μΐ cell layer of 0.4 % (w/v) Bacto agar (Difco, Detroit, 
MI,USA) in Growth Medium (containing 2000 cells) was plated on top of a 
1.8 ml lower layer of 1 % (w/v) agar in Growth Medium. The cell layer was 
covered with a 1 ml overlayer of 0.4 % (w/v) agar in Growth Medium. The 
plates were incubated at 37°C in a fully humidified atmosphere of 5% CO2 
in air. 
The image analysis system and the data editing process have been 
described in detail elsewhere (9). In short, a Quantimet 970 (Cambridge 
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Instruments, Buffalo, NY) image analyser was used. Cell cultures were 
monitored using pseudo-darkfield optics with an inverted microscope (ICM 
405 Zeiss, Oberkochen, Germany). Starting on the day of plating a 26 mm^ 
area in the center of each well was monitored daily, and the size, shape and 
location of all cells in the observation area were recorded. Custom-made 
software matching each cell/colony with its counterpart in previous 
observations provided the information on the individual growth history of 
each colony. Cell cultures were monitored daily for 6 days, starting on the 
day of plating (7 observations). The data presented summarize results 
obtained with three repetitive experiments. 
Categorization of growth patterns 
Individual growth rates of colonies, expressed as colony area 
doublings/day, were estimated as the slopes of the linear regression of the 
natural logarithm of colony area (μιντ) vs time (days) / ln2 by means of the 
least squares method. Cells for which the slope of the regression line was 
not significantly different from 0 (p > 0.05) were categorized as non-
growing cells. Cells for which the slopes of the regression lines were greater 
than zero over the entire observation period (overall slope), but zero during 
the last 5 looks only, (late slope), were categorized as cells with limited 
growth. Cells were considered as continuously growing when both slopes 
were greater than zero. 
Estimation of changes in growth fraction within a colony. 
Growth rates of colonies were assessed by monitoring the increase of 
colony area which is justifiable as long as the increase of colony area and 
cell number remains constant (9). However, a potential pitfall is a decrease 
of growth fraction (delayed cell death) within a colony without decrease in 
growth rate among the surviving cells which might result in an artificial 
decrease in growth rate of the total colony. Control experiments were done 
in order to assess whether growth slow down is due to decreased growth rate 
of all cells comprising a colony or due to decrease of growth fraction within 
a colony. The control experiments were set up according to the rational that 
if decrease in growth fraction within a colony was occuring, a three day 
121 
Chapter 6: Growth kinetics qfclonogenic cells following Anthracycline exposure 
delay period before plating cells in agar should resolve such phenomenon 
since the dead cells than would no longer be part of a existing colony. Thus, 
if delayed cell death did occur and caused growth slow down of a colony, 
one would expect an increase of non-growing cells when plating cells on day 
3 compared to day 0. In addition, one would expect the growth rates of the 
growing colonies plated on day 3 to be higher compared to cells plated on 
dayO. 
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RESULTS 
Colony formation of K562 cells 
The average number of objects monitored per well (which includes 
both single cells that did not grow as well as colonies emerging from 
dividing cells) was 153 ± 23 (N=30 wells). Growth rates of all objects 
observed were calculated. Untreated K562 cells exhibited heterogeneity in 
growth rates among the growing colonies. However, variation of growth 
rates was continuous and therefore no distinct subpopulations were 
distinguishable based on growth rates. The mean growth rate of all 
continuously growing untreated colonies, expressed as colony area 
doublings/day, was 1.01 ± 0.03 (N=266). 
Effect of Pox, Dnr. and Ida on the growth of individual colonies 
Table I. Effect of Doxorubicin, Daunorubicin, and ¡darubicin (2 h exposure) on the distribution 
of growth categories ofK562 cells in culture. 
drug exposure 
(μ^πτί) 
DoxO 
Dox 0 05 
DoxO 1 
Dox 0.3 
Dox 0 5 
DnrO 
Dnr 0 01 
Dnr 0 05 
DnrO 1 
Dnr 0.5 
IdaO 
Ida 0 01 
Ida 0 025 
Ida 0 05 
Ida 0.075 
non-growing 
(%) 
13-164 
11-14 
15-18 
21-34 
48-50 
5-12 
9-10 
10-12 
29-34 
42-44 
5-17 
11-17 
18-28 
64-26 
50-57 
limited 
growth 
(%) 
7-35 
12-32 
24-42 
38-39 
33-38 
6-9 
6-24 
24-27 
41-50 
41-43 
6-6 
15-15 
27-32 
24-46 
24-32 
continuously growing 
(%) 
52-76 
49-77 
40-61 
28-40 
12-19 
82-86 
66-85 
61-66 
21-25 
13-17 
77-89 
68-74 
50-55 
12-28 
18-19 
Range of 3 replicate experiments 
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Colonies of control cultures and cultures treated with varying 
concentrations of Dox, Dnr, and Ida were categorized according to their 
growth potential as non-growing, limited growth, or continuously growing 
(Table I). For each drug, the percentage of non-growing cells and the 
percentage of cells showing limited growth were increased with increasing 
drug concentrations. Comparable effects were observed with the three drugs 
studied, although they ocurred at different drug concentrations. 
In order to assess whether limited growth is due to cells going through a 
finite number of doublings or whether it is due to cell swelling because of 
delayed mitosis prior to cell death, the final areas of each of the 
cells/colonies categorized as limited growth were analyzed. The average 
initial area of all cells was 291 μπι . Assuming a spherical model for cell 
shape, an area of 291 μπτ corresponds to a cell diameter of 19.26 μπι. 
Applying the same model, a two-fold increase of cell diameter would result 
in an area of 1165 μπι, while a three-fold increase would result in an area 
of 2622 μπι2. The range from median to highest final areas observed in this 
category were 2042-8613 μπι2 for Dox, 988-3720 μπι2 for Dnr, and 1095-
3749 μπι2 for Ida. Thus, in these upper ranges of final areas it is 
inconceivable that the increase in area is due to cell swelling without cell 
division. Therefore, cell swelling, by virtue of its growth kinetics, will 
contribute to the limited growth category but not all the observed limited 
growth can be attributed to cell swelling. Analysis of drug effects on growth 
rate of the continuously growing colonies demonstrated a concentration-
dependent decrease with each of the three drugs tested. In figure 6.1 this is 
illustrated by the line graphs which show the increase of the average colony 
area over time (exclusively based on continuously growing colonies) for 
each drug. The distribution of the corresponding (individual) growth rates is 
represented in frequency distribution histograms. 
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FIGURE 6.1 
Growth 0/K562 cells following 2 h exposure to doxorubicin (A), daunorubicin (B), or idarubicin 
(C). For each drug concentration, the growth of continuously growing colonies (See Table I) is 
summarized by plotting the mean colony area vs time. The distribution of corresponding growth 
rates is depicted by the bar histograms. 
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In order to assess whether the observed growth slow down was 
attributable to partial delayed growth arrest within colonies, control 
experiments were performed involving delayed plating as described in the 
methods section. No differences in distribution of growth rates were 
observed when cells were plated on day 0 or day 3, demonstrating that cell 
kill within a colony is not likely to be a relevant phenomenon. As a 
representative example, figure 6.2 shows the growth of cells which were 
exposed to 0.3 pg/ml doxorubicin. However, an increase of the fraction of 
growth arrested cells was observed at the expense of the fraction of colonies 
displaying limited growth between cells plated on day 3 versus those plated 
on day 0. Since the sum of the two fractions is not affected this is probably 
due to the fraction of cells/ colonies which increased their area only during 
the first three days and then stopped. 
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FIGURE 6.2 
Growth of K562 cells following 2h exposure to 0.3 ßg/ml doxorubicin and plated on the same 
day (day 0) or after a three day waiting period (day 3). Pie slices correspond with no growth 
(solid), delayed arrest (hatched), or continuous growth (open). 
Dose-response curves were constructed by plotting the fraction of 
continuously growing cells against drug exposure concentrations. Curves 
were fitted according as previously described (10). Only minor differences 
were observed in reduction of the fraction of continuously growing cells by 
Dox and Dnr while Ida was as potent in reducing this fraction at 10% of the 
Dox or Dnr concentrations (figure 6.3A). 
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Figure 6.3 
Dose-response of 2 h exposure ofK562 cells to doxorubicin (circles), daunorubicm (squares), or 
idarubicin (triangles) on the fraction of surviving (continuously growing) cells (ЗА) and 
relationship between drug toxicity and corresponding growth rate of surviving cells (3B). The 
solid line in plot В represents the first order linear regression ¡me while the dotted lines 
represent the 95% confidence interval for the regression. 
In order to compare the effect of the three drugs on growth rate at 
equitoxic concentrations, the percentage of non-growers (including cells 
which showed limited growth) were plotted against the average growth rate 
of the corresponding continuously growing cells (figure 6.3B). For Dox, 
Dnr, and Ida at equitoxic drug concentrations no significant differences were 
observed in the reduction of growth rate of the continuously growing cells. 
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DISCUSSION 
Decrease in growth rate of K562 cells following short-term exposure 
to Dox was previously described (8). In the present study, utilizing an image 
analysis system that monitors the growth of individual colonies derived from 
a single cell, a concentration-dependent decrease in the growth rate of 
continuously growing colonies was observed consistent with the data 
obtained with flow cytometric analysis. In addition it is demonstrated that 
the observed decrease in growth rate of surviving cells following 
doxorubicin exposure is also observed following daunorubicin or Idarubicin 
exposure. 
By comparing the average growth rates during the last 5 days (late 
slope) with the average growth rates calculated by including the whole 
observation period (overall slope) it was obvious that with some drug 
concentrations, growth rates tended to decrease during the last 5 days. In 
principle, it should be possible to classify all observed growth patterns 
according to their deviation from simple exponential growth kinetics. 
However, such a classification would be arbitrary with regard to how many 
different classes one would wish to distinguish. Therefore, we used the 
simple exponential growth model to calculate growth rates and only 
discriminated limited growth from continuous growth. Thus, in those cases 
where growth characteristics deviate from simple exponential growth, the 
calculated growth rates will approximate the actual growth rates and will 
truly reflect changes in growth rates (slow down) but the calculations will 
not be perfect. 
The drug concentrations used in this study were choosen to be in the 
range of in vivo attainable plasma levels. In vivo plasma levels of Dox 
attained during a 2 h infusion of 40 mg/m2 are about 0.4 μg/ml (11,12). 
Peak plasma levels attained with 45 mg/m2 daunorubicin administered as a 
bolus injection reach 0.23 ±0.12 μg/ml (13) while peak plasma levels of Ida 
(10 mg/m2) administered as a bolus injection reach 0.05 ± 0.02 μg/ml (14). 
At comparable drug concentrations no major differences were observed in 
the effect of Dox and Dnr on the fraction of the continuously growing cells 
while Ida was as potent in reducing this fraction at 10% of the Dox or Dnr 
concentrations (figure 6.3A). These findings are consistent with the general 
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finding of Ida being a more potent drug in comparison to Dox and Dnr (4,5). 
However, at equitoxic drug concentrations (same reduction in growth 
fraction) the effects of the three anthracyclines on growth rate were 
comparable (figure 6.3B). Thus for the three anthracyclines studied there is 
a comparable relationship between reduction of growth fraction and 
reduction of growth rate of the surviving cells. The distribution between 
numbers of non-growers or limited growers should be interpreted with 
caution. Although the sum of the fraction of non-growers and limited 
growers was reproducable in repeated experiments (N=3) using the same 
drug exposures, variability was observed for the distribution between these 
two categories. This indicates that the method used to discriminate between 
these two categories might not be optimal and that it might be better to 
include both categories in one overall category of non-continuous growers. 
We did not implement this in Table I in order to emphasize that non-
continuous growth comprises more than just no-growth. The observed 
heterogeneity in colony growth rate in control cultures (see figure 6.1 ) might 
be due to the use of non-cloned cultures. The virtue of using uncloned cell 
populations however is that it mimics the in vivo situation more closely. 
In conclusion, all of the three anthracyclines studied induced a 
concentration-dependent decrease in growth fraction of K562 cells and a 
reduction of the growth rate of the surviving cells. Employment of the newly 
developed image analysis method allowed quantitation of heterogeneity in 
growth rates and discriminate among different drug effects on the growth 
kinetics of individual colonies in a heterogeneous cell population. It is 
conceivable that drug-induced growth slow down is relevant in vivo. 
Clinically, successful remission induction with these agents may reflect 
growth arrest (cell kill) of the majority of the malignant cells, but if relapse 
is a reflection of outgrowth of residual surviving cells one has to consider 
that these cells may exhibit perturbed growth kinetics (decreased growth 
rates) following remission induction. Since the sensitivity of these surviving 
cells to subsequent chemotherapy may be altered due to the perturbation it is 
important to recognize the phenomena. The subject of how the perturbed 
growth kinetics of surviving cells from first-line chemotherapy affects their 
sensitivity to second-line chemotherapy is subject of current investigation in 
our laboratory. 
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Chapter 7: Summary and General Conclusions 
Normal hematopoietic cells, leukemic cells and cell lines are models 
for the study of normal and malignant cell kinetics and of the factors that 
influence cell growth, cell development and cell elimination. From the 
concepts of Lajtha (1), Till et al. (2) and from studies of Skipper et al. (3) 
and Goldie and Coldman (4) a model of hematopoiesis has evolved which is 
now generally accepted. In short: there exists a stem cell compartment of 
multipotential progenitor cells, mostly in a resting or dormant state (GO). A 
small part of the stem cells is randomly recruited into the cell cycle, 
resulting in stem cell renewal and stem cell differentiation. During 
differentiation the stem cell capacity and the proliferation potential is 
gradually lost and the cell becomes a so-called transitional cell. The fully 
differentiated, mature end-cell has arrived in a permanent non-dividing state 
and finally dies. During homeostasis the production, maturation, and 
function of the hematopoietic cells are in delicate balance. In leukemia, this 
balance is disturbed due to an aberrant maturational mechanism by which 
the cells become arrested at a certain stage of differentiation leading to an 
accumulation of a distinct immature cell type which suppresses the normal 
hematopoiesis. In the chronic, or well-differentiated leukemias, unregulated 
cell proliferation, accumulation of leukemic cells, and elevated white cell 
count dominate, whereas differentiation and maturation of the leukemic cells 
may be largely preserved. In the acute leukemias, unregulated proliferation 
occurs also, but maturation of the leukemic progenitors is profoundly 
impaired. 
Therapy of the chronic leukemias is directed toward suppressing the 
excessive proliferation to reduce the accumulation of leukemic cells, 
whereas, in the acute leukemias, very intensive treatment is used to 
obliterate the leukemic clone. The standard treatment of acute myeloid 
leukemia is chemotherapy based on a combination of an anthracycline drug 
(Doxorubicin (Dox); Daunorubicin (Dnr); or Idarubicin (Ida)) and cytosine-
arabinoside. Although the initial treatment with this drug combination 
appears very effective with remission induction in approximately 80 % of 
the cases, the majority of the patients will relapse and the successrate and 
disease-free periods following subsequent treatments declines. Ultimately, 
many patients present with resistant disease. Drug resistance can be an 
innate or acquired property of a cell. There exists circumstantial evidence 
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that acquired resistance is due to selection of drug resistant tumor stem cells 
which escape from drug treatment (5-7). Recent advances in cell biology 
with respect to growth regulation and drug sensitivity include the tumor 
suppressor gene p-53 (8), the apoptosis-inhibitor gene bcl-2 (9) and the 
multidrug resistance gene mdr-1 (10). Little attention has been paid untili 
now to the relation between the cycling state and the cell cycle phase of the 
tumor stem cells and their resistance to cytotoxic drugs. 
Our investigations have been directed to this aspect of escape from drug 
cytotoxicity, assuming that tumor stem cells may escape from cytotoxic cell 
elimination because a large part of the stem cells are in a quiescent, dormant 
state (GO) making them less sensitive to the toxic effects of anticancer drugs 
related to their low metabolic activity. 
The aim of this study was to determine how several aspects of cell 
proliferation may influence the toxicity of the most commonly used 
anthracyclines at clinically relevant drug concentrations and how cell 
division as such may be effected by exposure to these drugs. 
Chapter 1 introduces the relatively new anthracycline drug Idarubicin 
(Ida) by summarizing laboratory and clinical data compared to its parent 
drug Daunorubicin (Dnr). In addition, a brief overview is given concerning 
cell proliferation and the study of cell kinetic parameters and the relevance 
of studying these parameters in relation to drug efficacy. 
Chapter 2 describes cellular drug uptake and retention studies in 
relation to the cell cycle. Most drugs, in order to be effective have to be 
taken up by the cell. Therefore, cellular uptake and retention of a drug are 
important parameters to be considered. It is demonstrated that uptake of Ida, 
Dnr and Doxorubicin (Dox) increases progressively from the onset of the 
cell cycle (Gl-phase) to its completion (M-phase). The relative fraction of 
drug retained following an extensive cell wash procedure was significantly 
higher for Dox and Dnr compared to Ida but was independent of the cell 
cycle phase. Drug toxicity as measured by inhibition of DNA synthesis 
showed a similar gradual increase from Gl to M phase demonstrating that 
cell cycle phase dependency of drug toxicity applies to all three 
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anthracyclines studied. 
Chapter 3 describes the relation between the cycling state of normal 
human hematopoietic cells and their sensitivity to Dox. In addition to being 
in an actively cycling state, cells can be dormant. Dormant cells that retain 
the capacity to divide following an appropriate stimulus are referred to as 
GO cells. Drug sensitivity of GO cells (T-lymphocytes) was compared with 
that of their stimulated (cycling) counterparts. The Dox concentration which 
inhibited DNA synthesis in 50% of the lymphocytes was significantly lower 
in case of drug exposure of proliferating lymphocytes compared to non-
proliferating lymphocytes. These proliferation-dependent differences were 
not related to differences in cellular drug uptake or retention. Proliferation-
dependent differences in drug sensitivity were found also for human bone 
marrow progenitor cells which give rise to cells of the granulocyte-
macrophage lineage (CFU-GM). Thus, quiescent, but potentially 
proliferative cells (GO cells) are relatively resistant to Dox. 
In Chapter 4 the proliferation-dependent toxicity of Dox towards 
normal (CFU-GM) and leukemic (CFU-L) human bone marrow progenitors 
was compared to that of Ida. Ida appeared to be the most potent drug in all 
experimental settings, regardless the proliferative state or origin (normal or 
leukemic) of the cell type under investigation. The major metabolite of Ida, 
Idarubicinol (Idaol), showed intermediate toxicity compared to Ida and Dox. 
Significant enhancement of toxicity by growth stimulation was observed for 
Dox vs CFU-GM and a strong trend vs CFU-L. The data demonstrated that 
proliferation-dependent toxicity of Dox was more pronounced for CFU-GM 
than for CFU-L. In the experimental settings used, Ida and Idaol toxicity 
appeared proliferation-independent. 
Chapter 5 describes the influence of Dox upon cell proliferation. 
Initial experiments studied the effect of Dox upon cell proliferation with use 
of DNA-flow cytometry. Molt-4 cells and K562 cells were exposed to 
different concentrations of Dox. After a 2 hrs incubation period a reversible 
and dose-dependent accumulation of cells at the G2+M compartment was 
observed. Maximum accumulation occurred between 16 and 30 hrs which 
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gradually restored within 60 hrs after exposure. The accumulation shows 
that Dox induces a temporary block in the cell cycle traverse at the G2+M 
boundery. Incubation of the cells with the thymidine analogue iododeoxy-
uridine (IdUrd) results in IdUrd incorporation into the cells' DNA during S-
phase. Subsequent two-parameter IdUrd/DNA flow cytometry, allows the 
measurement of the duration of the cell cycle time. Using this approach, the 
cell cycle traverse following exposure to Dox was studied. In both cell lines 
studied (Molt-4, K562) a dose-dependent deceleration of the cell cycle 
traverse was observed, persisting for at least 48 hrs. The observed cell cycle 
deceleration has to be taken into consideration when interpreting short-term 
survival assays since multiple cellular parameters will be effected by these 
altered cell cycle kinetics. Artificially high drug effects may be observed 
when the alteration of a parameter studied is considered only to be caused 
by cell kill. 
Chapter 6 describes the effects of Dox, Dnr, and Ida on the growth 
kinetics of clonogenic cells. The formation of individual colonies in semi-
solid culture was monitored by a newly developed assay, the individual 
Colony Formation Assay (iCFA). Drug effects were evaluated using a short 
term exposure (2 h) at clinically achievable drug plasma concentrations. 
Following drug exposure, heterogeneity in growth patterns was observed 
which was categorized into three distinct types, being 1 ) continuous growth 
at a decreased growth rate; 2) limited growth; and 3) no growth. At 
equitoxic drug concentrations, comparable changes in proliferation rate were 
observed for each of the three anthracyclines studied. It is demonstrated that 
the fraction of clonogenic cells which escape drug-induced growth arrest 
with therapeutically achievable drug concentrations, display a significant 
decrease in growth rate. 
In conclusion, 
Cellular pharmacokinetics of the three anthracyclines studied are 
different but their cell cycle phase dependency is similar. 
Resting cells which retain the capacity to divide are relatively resistant 
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to doxorubicin. 
Proliferation dependent differences of Dox toxicity are more 
pronounced for CFU-GM than for CFU-L. 
Ida is more potent than Dox regardless of the proliferative state of the 
cells. 
Ida toxicity is proliferation-independent and exerts a less outspoken 
differential toxicity towards normal and leukemic cells compared to 
Dox. 
Following exposure to Dox, Dnr, or Ida, surviving cells display a 
decreased growth rate. 
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SAMENVATTING 
Normale bloedcellen, leukemische cellen en cellijnen kunnen worden 
gebruikt als modelsystemen ter bestudering van de celkinetiek van normale 
en kwaadaardige celgroei, -ontwikkeling en -eliminatie en factoren die 
hierop van invloed kunnen zijn. 
Op basis van de ideeën van Lajtha (1), Till et al. (2) en studies van Skipper 
et al. (3) en Goldie en Coldman (4) is een model voor de hematopoiese 
ontwikkeld wat nu algemeen geaccepteerd is. Kort samengevat: er bestaat 
een zgn stamcelcompartiment bestaande uit multipotente progenitor cellen 
die zich in een rustende (uit cyclus zijnde) staat bevinden. Een klein deel 
van de stamcellen wordt onwillekeurig gerecruiteerd om te gaan delen en 
zodoende ontstaan er enerzijds nieuwe stamcellen en anderzijds de 
nakomelingen welke verder differentieren en geleidelijk het vermogen tot 
celdeling gaan verliezen. De volledig gedifferentieerde, 'volwassen' 
eindstadiumcel bevindt zich in een permanente rustende staat en zal 
uiteindelijk sterven. 
Onder normale omstandigheden zijn de aanmaak, ontwikkeling en 
functie van de bloedcellen in een delicaat evenwicht. In geval van leukemie 
is de normale ontwikkeling van de cellen verstoord omdat de cellen in een 
bepaald ontwikkelingsstadium van de differentiatie zijn gearresteerd wat 
leidt tot een accumulatie van een bepaald onvolkomen ontwikkeld celtype 
welke de normale hematopoiese onderdrukt. Het celtype en het 
ontwikkelingsstadium bepalen het soort leukemie. Chronische leukemie 
wordt gekarakteriseerd door ongecontroleerde celproliferatie, accumulatie 
van leukemische cellen, en verhoogde witte bloedcelwaarden, terwijl de 
ontwikkeling en differentiatie van de leukemische cellen in het algemeen 
behouden blijft. Ongecontroleerde celdeling vindt ook plaats in acute 
leukemie maar tevens is de ontwikkeling van de cellen ontregeld. 
Behandeling van chronische leukemie is er op gericht de buitensporige 
proliferatie en de accumulatie van de leukemische cellen te remmen terwijl 
in geval van acute leukemie intensieve therapie toegepast wordt met het doel 
de leukemisch kloon uit te schakelen. De standaard behandeling van acute 
myeloide leukemie is chemotherapie gebaseerd op een combinatie van een 
anthracycline drug (doxorubicine (Dox), daunorubicine (Dnr), of Idarubicine 
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(Ida)) in combinatie met cytosine-arabinoside. Hoewel deze behandeling op 
het eerste gezicht effectief lijkt met remissie-inductie in 80 % van de 
gevallen, krijgt toch de meerderheid (80 %) vroeger of later een recidief. De 
kans op remissie en de duur van de ziekte-vrije periode na opeenvolgende 
behandelingen neemt vervolgens af en vele patiënten ontwikkelen 
uiteindelijk resistentie. Resistentie kan een intrinsieke of een verworven 
eigenschap zijn van een cel. Er zijn indirecte bewijzen dat verworven 
resitentie een gevolg zou kunnen zijn van selectie van resistente cellen 
welke aan de behandeling ontsnappen (5-7). 
Recente ontwikkelingen in de moleculaire celbiologie mbt groei 
regulatie en gevoeligheid voor cytostatica omvatten studies mbt het tumor-
suppressor gen p-53 (8), het bcl-2 gen in associatie met remming van 
geprogrameerde celdood (apoptose) (9), en het multidrug resistentie gen 
mdr-1 (10). Tot op heden is relatief weinig aandacht besteed aan de relatie 
tussen de proliferatie activiteit en de celcyclusfase van de tumorcellen en 
hun gevoeligheid voor cytostatica. De studies beschreven in dit proefschrift 
waren erop gericht deze aspecten van resistentie te bestuderen met de 
veronderstelling dat tumor stamcellen ontsnappen aan cytostatica 
blootstelling omdat een deel van de stamcellen zich in een rustende (GO) 
staat bevinden. Het doel van de studie was te bepalen hoe diverse aspecten 
van celproliferatie de effectiviteit van klinisch relevante concentraties van 
anthracyclinen beïnvloeden en hoe de celdeling opzich beïnvloed wordt door 
de blootstelling aan de anthracyclinen. 
Hoofdstuk 1 introduceert het relatief nieuwe anthracycline-derivaat 
Idarubicine (Ida) met een samenvatting van laboratorium data en klinische 
data in vergelijking met Dnr. Bovendien wordt een overzicht gegeven van 
celdeling, het analyseren van celkinetische parameters en de relevantie 
hiervan met betrekking tot drug effectiviteit. 
Hoofdstuk 2 beschrijft studies gericht op cellulaire opname en retentie 
van anthracyclinen in relatie tot de celcyclus. Voor de meeste 
celdelingsremmende middelen (cytostatica) geldt dat deze opgenomen 
dienen te worden door de cel alvorens ze effectief kunnen zijn. De cellulaire 
opname en retentie van cytostatica zijn daarom parameters welke de 
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effectiviteit van cytostatica kunnen beïnvloeden. Aangetoond wordt dat de 
opname van Dox, Dnr en Ida toeneemt met de progressie van het begin van 
de celdelingscyclus (Gl-fase) naar het einde van de cyclus (M-fase). De 
relatieve fractie welke intracellulair behouden blijft na intensieve 
wasprocedures is significant groter voor Dox en Dnr in vergelijking met Ida 
maar deze verschillen werden gevonden in alle fases van de celcyclus. Drug 
toxiciteit werd gemeten door middel van bepaling van DNA synthese. Het 
vermogen om DNA te synthetiseren na blootstelling aan de anthracyclinen 
nam geleidelijk af met progressie in de celcyclus. De celcyclusfase-
afhankelijke verschillen in effectiviteit zijn dus vergelijkbaar voor de drie 
anthracyclinen. 
Hoofdstuk 3 beschrijft de relatie tussen de proliferatie activiteit van 
normale humane bloedcellen en hun gevoeligheid voor Dox. Behalve dat 
cellen continu actief delen kunnen cellen zich ook in een rustend stadium 
bevinden. Rustende cellen die het vermogen tot celdeling behouden in 
respons aan een adequate stimulus worden GO-cellen genoemd. 
Gevoeligheid van GO cellen (T-lymfocyten) voor Dox werd vergeleken met 
dat van hun gestimuleerde tegenhangers. De Dox concentratie welke DNA 
synthese remde in 50% van de lymfocyten populatie (IC50) was significant 
lager voor de gestimuleerde lymfocyten in vergelijking tot de rustende 
lymfocyten. De proliferatie-afhankelijke gevoeligheid was onafhankelijk van 
drug opname en retentie. Overeenkomstige verschillen konden worden 
aangetoond voor normale beenmerg progenitor cellen (CFU-GM). Dus 
normale bloed / beenmerg cellen die zich in een rustend stadium bevinden 
zijn relatief ongevoelig voor Dox in vergelijking tot hun 'in cyclus' zijnde 
tegenhangers. 
In Hoofdstuk 4 wordt de proliferatie-afhankelijke gevoeligheid voor 
Dox van normale beenmerg progenitor cellen (CFU-GM) vergeleken met dat 
van leukemische beenmerg cellen (CFU-L) en wordt onder dezelfde 
experimentele omstandigheden de toxiciteit van Dox vergeleken met dat van 
Ida. Ida bleek onder alle condities het meest effectieve cytostaticum, 
ongeacht de delingsactiviteit of origine (normaal of leukemisch) van de 
cellen. De toxiciteit van de voornaamste metaboliet van Ida (Idarubicinol) 
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was intermediair tussen Dox en Ida. Significante verhoging van de 
gevoeligheid voor Dox werd gevonden voor normale CFU-GM na 
groeistimulatie. Voor leukemische cellen (CFU-L) werd een sterke tendens 
waargenomen voor verhoogde gevoeligheid maar de verschillen met de 
ongestimuleerde cellen waren, in tegenstelling tot wat waargenomen werd 
met normale CFU-GM, statistisch niet significant. De waarnemingen tonen 
aan dat de proliferatie-afhankelijke gevoeligheid voor Dox meer 
uitgesproken is voor normale beenmergcellen dan voor leukemische 
beenmergcellen. Onder de gebruikte experimentele condities was de 
toxiciteit van Ida en Ida-ol onafhankelijk van de proliferatie activiteit van de 
cellen. 
Hoofdstuk 5 beschrijft de effecten van Dox op de celdeling. In de 
eerste serie experimenten werden de effecten van Dox op de celdeling 
bestudeerd mbv DNA-flowcytometrie. Molt-4 cellen en K562 cellen werden 
blootgesteld aan verschillende concentraties Dox. Na een 2 uurs incubatie 
werd een reversibele en dosis-afhankelijke accumulatie waargenomen van 
cellen in de G2+M fase van de celcyclus. Maximale accumulatie werd 
waargenomen na verloop van 16-30 uur waarna de 'normale' verdeling over 
de celcyclusfasen weer werd waargenomen na verloop van 60 uur na 
blootstelling. De accumulatie toont aan dat Dox een tijdelijke blokkade 
veroorzaakt in het verloop van de celcyclus ten hoogte van de G2+M fase. 
Blootstelling van cellen aan het thymidine analogon iododeoxyuridine 
(IdUrd) resulteert in IdUrd inbouw in DNA gedurende de S-phase. Twee-
parameter IdUrd/DNA flowcytometrie stelt de onderzoeker vervolgens 
instaat om de celcyclustijd te bepalen. Van deze methode gebruikmakend 
werd in een tweede serie experimenten de celcyclus bestudeerd na 
blootstelling aan Dox. In beide onderzochte cellijnen (Molt-4, K562) werd 
een dosis-afhankelijke vertraging in de celcyclus waargenomen welke 
tenminste gedurende 48 uur aanwezig was. De waargenomen 
celcyclusvertraging zou in acht genomen moeten worden bij de interpretatie 
van kort-durende overlevingsassays omdat vele parameters beïnvloed 
kunnen worden door de veranderde celkinetiek met niet in de laatste plaats 
het aantal nakomelingen in een vast tijdsbestek. Dit laatste is met name van 
belang mbt zgn klonogene assays. Artificieel sterke drug effecten zouden 
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worden waargenomen als de verandering van de parameter in kwestie alleen 
zou worden geïnterpreteerd op basis van celdood. 
De effecten van Dox, Dnr en Ida op de celdeling van individuele 
klonogene cellen werd vergeleken in Hoofdstuk 6. De ontwikkeling van 
individuele kolonies in semi-solide (agar) kweekbodems werd vervolgd met 
behulp van een nieuw ontwikkelde beeldververwerkingassay. De gebruikte 
concentraties van de cyctostatica werden zodaning gekozen dat ze de 
concentraties die in de patient bereikt kunnen worden weerspiegelden. Ten 
gevolge van de blootstelling werd een heterogene respons in de cellen 
waargenomen die gekarakteriseerd kon worden in drie verschillende 
categorien, nl: 1. continue groei, zij het vertraagd; 2. beperkte groei, en 3. 
geen groei. Blootstelling aan vergelijkbare concentraties van de drie 
cytostatica resulteerde in verschillende toxiciteit maar bij een vergelijkbare 
toxiciteit waren de effecten mbt de voornoemde drie categorieën hetzelfde. 
Zodoende werd dus aangetoond dat na blootstellling aan therapeutisch 
relevante concentraties van alle drie de anthracyclinen geldt dat voor cellen 
die overleven de groei aanmerkelijk vertraagd is. 
Samenvattend zijn de meest significante bevindingen dat: 
ondanks dat de drie anthracyclinen zich verschillend gedragen mbt 
hun cellulaire farmacokinetiek, de wijze waarop de celcyclusfase hun 
toxiciteit beïnvloedt hetzelfde is. 
normale bloed / beenmergcellen die zich in een rustend stadium 
bevinden relatief ongevoelig zijn voor Dox in vergelijking tot hun 'in 
cyclus' zijnde tegenhangers. 
de delings-afhankelijke toxiciteit van Dox meer uitgesproken is voor 
normale beenmergcellen dan voor leukemische beenmergcellen. 
Idarubicine een potenter cytostaticum is dan Doxorubicine, ongeacht 
de delingsactiviteit van de cellen. 
de toxiciteit van Idarubicine onafhankelijk is van de delingsactiviteit 
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van de cellen. 
na blootstelling aan Doxorubicine, Daunorubicine, of Idarubicine, de 
overlevende cellen een vertraagde celgroei ondergaan. 
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